Solid state forms of substituted pyrazolopyrimidines and uses thereof
Patent Information
- Application Number
- TW110140063
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-10-30
- Filing Date
- 2021-10-28
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2041-10-27
AI Technical Summary
Existing substituted pyrazolopyrimidines lack optimal characteristics for therapeutic use, including high affinity for USP1, duration of deactivation, oral bioavailability, solubility, and stability, which are crucial for safety, efficacy, and manufacturing feasibility.
Development of solid state forms of substituted pyrazolopyrimidines, such as crystalline and amorphous forms, characterized by specific XRPD patterns, and pharmaceutically acceptable salts and co-crystals, to enhance properties like chemical stability, solubility, and formulation feasibility.
The solid state forms improve the balance of properties necessary for pharmaceutical use, enabling the preparation of stable and effective dosage forms with enhanced safety and efficacy.
Smart Images

Figure TWG2TB001919894_001 
Figure TWG2TB001919894_002 
Figure TWG2TB001919894_003
Abstract
Description
Technical Field
[0001] This invention relates to the solid form of substituted pyrazolopyrimidine, pharmaceutical compositions thereof, methods for treating cancer by administering one or more solid forms of substituted pyrazolopyrimidine, and methods for preparing the solid form of substituted pyrazolopyrimidine. Prior Technology
[0002] Substituted pyrazolopyrimidines are inhibitors of ubiquitin-specific processing protease 1 (USP1), such as 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III).
[0003] Not all USP1 inhibitor compounds possess the characteristics that make them optimally suited as therapeutic agents. Some of these characteristics include high affinity for USP1, duration of USP1 deactivation, oral bioavailability, solubility, and stability (e.g., reconstitution ability, crystallization ability, or shelf life). Favorable characteristics can lead to improved safety, tolerability, efficacy, therapeutic index, patient compliance, cost-effectiveness, and ease of manufacture.
[0004] Furthermore, the isolation and commercial-scale preparation of substituted pyrazolopyrimidines in solid form present many challenges, such as 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl) -3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and corresponding pharmaceutical formulations having acceptable solid-state properties (including chemical stability, thermal stability, solubility, hygroscopicity and / or particle size), compound manufacturability (including yield, impurity rejection during crystallization, filtration characteristics, drying characteristics and grinding characteristics) and formulation feasibility (including stability with respect to pressure or compressive forces during ingot preparation).
[0005] Therefore, there is a need for one or more solid forms of substituted pyrazolopyrimidines, such as 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III), which have an acceptable balance of these properties and can be used to prepare pharmaceutically acceptable solid dosage forms. Summary of the Invention
[0006] [] []
[0007] In one state, the present invention relates to the solid form of the compound of formula (I): (I), Or a medically acceptable salt; in: R is a C1-3 alkyl group; and X1 and X2 are groups independently chosen from N and C.
[0008] In some embodiments, the solid form is the solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II), Or a medically acceptable salt.
[0009] In some embodiments, the solid form is the crystalline form of the compound of formula (II). In some embodiments, the crystalline form is its hydrate, anhydrous form, or solvate. In some embodiments, the solvate is a dichloromethane solvate.
[0010] In some embodiments, the solid form is an amorphous form of the compound of formula (II). In some embodiments, the amorphous form is its hydrate, anhydrous form, or solvate.
[0011] In some embodiments, the solid form of the compound of formula (II) is selected from the group consisting of: a) Crystalline form A, characterized by XRPD spectra with peaks at 14.3 ± 0.2, 21.5 ± 0.2, and 21.8 ± 0.2º 2θ; b) Crystalline form C, characterized by XRPD peaks at 14.2 ± 0.2, 17.0 ± 0.2, and 19.1 ± 0.2º 2θ; c) Crystalline form D, characterized by XRPD spectra with peaks at 13.9 ± 0.2, 15.2 ± 0.2, and 19.3 ± 0.2º 2θ; d) Crystalline form E, characterized by peaks in its XRPD spectrum at 10.6 ± 0.2, 18.7 ± 0.2, and 20.9 ± 0.2º 2θ; and e) Crystalline form F, wherein form F is characterized by XRPD spectra having peaks at 10.7 ± 0.2, 14.3 ± 0.2 and 21.8 ± 0.2º 2θ.
[0012] In some embodiments, the solid form of the compound of formula (II) is selected from the group consisting of: a) Crystalline form A, characterized by XRPD spectra with peaks at 14.3 ± 0.2, 21.5 ± 0.2, and 21.8 ± 0.2º 2θ; b) Crystalline form C, characterized by XRPD peaks at 14.2 ± 0.2, 17.0 ± 0.2, and 19.1 ± 0.2º 2θ; c) Crystalline form D, characterized by XRPD spectra with peaks at 13.9 ± 0.2, 15.2 ± 0.2, and 19.3 ± 0.2º 2θ; and d) Crystalline form E, wherein form E is characterized by XRPD spectra with peaks at 10.6 ± 0.2, 18.7 ± 0.2, and 20.9 ± 0.2º 2θ.
[0013] In some embodiments, the solid form of the compound of formula (II) is crystalline form A. In some embodiments, crystalline form A is characterized by the XRPD spectrum shown in Figure 1. In some embodiments, crystalline form A is characterized by an endothermic peak at approximately 165 °C, as determined by DSC. In some embodiments, crystalline form A is characterized by the DSC pattern shown in Figure 2. In some embodiments, crystalline form A is characterized by a loss of approximately 0.93 wt% between room temperature and approximately 150 °C, as determined by TGA. In some embodiments, crystalline form A is characterized by the TGA pattern shown in Figure 2.
[0014] In some embodiments, crystalline form A is characterized by at least two of the following: a) the XRPD pattern shown in FIG1; b) the DSC pattern shown in FIG2; or c) the TGA pattern shown in FIG2.
[0015] In some embodiments, crystalline form A substantially does not contain other polymorphic forms. In some embodiments, crystalline form A has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
[0016] In some embodiments, crystalline form A has a unit cell that is specified as a monoclinic crystal system. In some embodiments, crystalline form A has a unit cell with a value of about 12.054 Å, a value of about 8.775 Å, and a value of about 24.837 Å. In some embodiments, crystalline form A has a unit cell with a volume of about 2603.68 ų.
[0017] In another embodiment, the invention relates to a mixture comprising crystalline form A and a second solid form of a compound of formula (II). In some embodiments, the invention relates to a mixture comprising a majority of crystalline form A compared to other solid forms of a compound of formula (II). The composition of the mixture of solid forms disclosed herein can be determined using methods known in this art (see, for example, Varasterh, M. et al., Int. J. Pharm. 366(1-2): 74-81 (2009)).
[0018] In some embodiments, the solid form of the compound of formula (II) is crystalline form C. In some embodiments, crystalline form C is characterized by the XRPD pattern shown in Figure 3.
[0019] In some embodiments, crystalline form C substantially does not contain other polymorphic forms. In some embodiments, crystalline form C has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
[0020] In another embodiment, the invention relates to a mixture comprising a crystalline form C and a second solid form of a compound of formula (II). In some embodiments, the invention relates to a mixture comprising a majority of the crystalline form C compared to other solid forms of the compound of formula (II).
[0021] In some embodiments, the solid form of the compound of formula (II) is crystalline form D. In some embodiments, crystalline form D is characterized by the XRPD pattern shown in Figure 4.
[0022] In some embodiments, crystalline form D substantially does not contain other polymorphic forms. In some embodiments, crystalline form D has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
[0023] In another embodiment, the invention relates to a mixture comprising crystalline form D and a second solid form of a compound of formula (II). In some embodiments, the invention relates to a mixture comprising mostly crystalline form D compared to other solid forms of a compound of formula (II).
[0024] In some embodiments, the solid form of the compound of formula (II) is crystalline form E. In some embodiments, crystalline form E is characterized by the XRPD spectrum shown in FIG5. In some embodiments, crystalline form E is characterized by an endothermic peak at approximately 107 °C, as determined by DSC. In some embodiments, crystalline form E is characterized by the DSC pattern shown in FIG6. In some embodiments, crystalline form E is characterized by a loss of approximately 13.5 wt% between room temperature and approximately 200 °C, as determined by TGA. In some embodiments, crystalline form E is characterized by the TGA pattern shown in FIG6.
[0025] In some embodiments, the crystalline form E is characterized by at least two of the following: a) the XRPD pattern shown in FIG5; b) the DSC pattern shown in FIG6; or c) the TGA pattern shown in FIG6.
[0026] In some embodiments, crystalline form E substantially does not contain other polymorphic forms. In some embodiments, crystalline form E has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
[0027] In another embodiment, the invention relates to a mixture comprising a crystalline form E and a second solid form of a compound of formula (II). In some embodiments, the invention relates to a mixture comprising mostly crystalline form E compared to other solid forms of a compound of formula (II).
[0028] In some embodiments, the solid form of the compound of formula II is crystalline form F. In some embodiments, crystalline form F is characterized by the XRPD spectrum shown in Figure 25. In some embodiments, crystalline form F is characterized by an endothermic peak at approximately 157°C, as determined by DSC. In some embodiments, crystalline form F is characterized by the DSC pattern shown in Figure 26.
[0029] In some embodiments, the crystalline form F is characterized by at least one of the following: a) the XRPD pattern shown in Figure 25; or b) the DSC pattern shown in Figure 26.
[0030] In some embodiments, crystalline form F substantially does not contain other polymorphic forms. In some embodiments, crystalline form F has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
[0031] In another embodiment, the invention relates to a mixture comprising a crystalline form F and a second solid form of a compound of formula (II). In some embodiments, the invention relates to a mixture comprising a majority of the crystalline form F compared to other solid forms of a compound of formula (II).
[0032] In some embodiments, the solid form of the compound of formula (II) is a pharmaceutically acceptable salt of the compound of formula (II).
[0033] In some embodiments, a pharmaceutically acceptable salt is formed between a compound of formula (II) and a pharmaceutically acceptable acid. In some embodiments, the pharmaceutically acceptable acid is selected from 1-hydroxy-2-naphtholic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactobionic acid, gentian acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, propionic acid, etc. The group consisting of diacid, R-mandelic acid, methanesulfonic acid, mucilage, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethoxymaltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, pharmaceutically acceptable acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentianic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, pharmaceutically acceptable acids are benzoic acid derivatives. In some embodiments, pharmaceutically acceptable acids are benzoic acid derivatives substituted with one or more hydroxyl groups. In some embodiments, pharmaceutically acceptable acids are benzoic acid derivatives substituted with one hydroxyl group. In some embodiments, a benzoic acid derivative substituted with one hydroxyl group is salicylic acid. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxyl groups. In some embodiments, a benzoic acid derivative substituted with two hydroxyl groups is gentic acid. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxyl groups. In some embodiments, a benzoic acid derivative substituted with three hydroxyl groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentic acid, and gallic acid. In some embodiments, a pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, a pharmaceutically acceptable acid is gentic acid. In some embodiments, a pharmaceutically acceptable acid is benzoic acid. In some embodiments, a pharmaceutically acceptable acid is salicylic acid. In some embodiments, a pharmaceutically acceptable acid is gallic acid.
[0034] In some embodiments, the solid form of the compound of formula (II) is the crystalline form of a pharmaceutically acceptable salt of the compound of formula (II). In some embodiments, the crystalline form of the pharmaceutically acceptable salt is its hydrate, anhydrous form, or solvate.
[0035] In some embodiments, the solid form of the compound of formula (II) is an amorphous form of a pharmaceutically acceptable salt of the compound of formula (II). In some embodiments, the amorphous form of the pharmaceutically acceptable salt is its hydrate, anhydrous form, or solvate.
[0036] In some embodiments, the pharmaceutically acceptable salt of the compound of formula (II) is a hydrochloride. In some embodiments, the hydrochloride is in crystalline form 1, characterized by an XRPD spectrum having peaks at 12.5 ± 0.2, 22.4 ± 0.2, and 23.9 ± 0.2º 2θ. In some embodiments, the hydrochloride is characterized by the XRPD spectrum shown in FIG7. In some embodiments, the hydrochloride is characterized by an endothermic peak at about 142.1 °C, as determined by DSC. In some embodiments, the hydrochloride is characterized by the DSC form shown in FIG8. In some embodiments, the hydrochloride is characterized by a loss of about 4.04 wt% between about 30 °C and about 100 °C, as determined by TGA. In some embodiments, the hydrochloride is characterized by the TGA form shown in FIG8.
[0037] In some embodiments, the crystalline form 1 is characterized by at least two of the following: a) the XRPD pattern shown in FIG7; b) the DSC type shown in FIG8; or c) the TGA type shown in FIG8.
[0038] In some embodiments, crystalline form 1 is substantially free of other polymorphic forms. In some embodiments, crystalline form 1 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
[0039] In another embodiment, the invention relates to a mixture comprising a crystalline form 1 and a second solid form of a compound of formula (II). In some embodiments, the invention relates to a mixture comprising mostly crystalline form 1 compared to other solid forms of a compound of formula (II).
[0040] In some embodiments, the solid form of the compound of formula (II) is a pharmaceutically acceptable cocrystal of the compound of formula (II) and a second pharmaceutically acceptable compound.
[0041] In some embodiments, the pharmaceutically acceptable eutectic system is formed between a compound of formula (II) and a pharmaceutically acceptable acid. In some embodiments, the pharmaceutically acceptable acid is selected from 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactobionic acid, gentian acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, propionic acid, etc. The group consisting of diacid, R-mandelic acid, methanesulfonic acid, mucilage, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethoxymaltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, pharmaceutically acceptable acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, pharmaceutically acceptable acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentic acid. In some embodiments, pharmaceutically acceptable acids are benzoic acid derivatives. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxyl groups. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxyl group. In some embodiments, a benzoic acid derivative substituted with one hydroxyl group is salicylic acid. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxyl groups. In some embodiments, a benzoic acid derivative substituted with two hydroxyl groups is gentic acid. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxyl groups. In some embodiments, a benzoic acid derivative substituted with three hydroxyl groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentic acid, and gallic acid. In some embodiments, a pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, a pharmaceutically acceptable acid is gentic acid. In some embodiments, a pharmaceutically acceptable acid is benzoic acid. In some embodiments, a pharmaceutically acceptable acid is salicylic acid. In some embodiments, a pharmaceutically acceptable acid is gallic acid.
[0042] In some embodiments, the pharmaceutically acceptable cocrystal of the compound of formula (II) is a gentic acid cocrystal. In some embodiments, the gentic acid cocrystal is crystalline form 2, characterized by an XRPD spectrum having peaks at 16.6 ± 0.2, 18.7 ± 0.2, and 22.5 ± 0.2º 2θ. In some embodiments, the gentic acid cocrystal is characterized by the XRPD spectrum shown in FIG9. In some embodiments, the gentic acid cocrystal is characterized by an endothermic peak at approximately 186.0 °C, as determined by DSC. In some embodiments, the gentic acid cocrystal is characterized by the DSC morphology shown in FIG10. In some embodiments, the gentic acid cocrystal is characterized by a loss of approximately 3.17 wt% between room temperature and approximately 170 °C, as determined by TGA. In some embodiments, the gentic acid cocrystal is characterized by the TGA morphology shown in FIG10.
[0043] In some embodiments, the crystalline form 2 is characterized by at least two of the following: a) the XRPD pattern shown in FIG9; b) the DSC pattern shown in FIG10; or c) the TGA pattern shown in FIG10.
[0044] In some embodiments, crystalline form 2 is substantially free of other polymorphic forms. In some embodiments, crystalline form 2 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
[0045] In some embodiments, crystal form 2 has a unit cell that is specified as a monoclinic crystal system. In some embodiments, crystal form 2 has a unit cell with a value of about 11.113 Å, a value of about 12.356 Å, and a value of about 24.048 Å. In some embodiments, crystal form 2 has a unit cell with a volume of about 3223.93 ų.
[0046] In another embodiment, the invention relates to a mixture comprising crystalline form 2 and a second solid form of the compound of formula (II). In some embodiments, the invention relates to a mixture comprising mostly crystalline form 2 compared to other solid forms of the compound of formula (II).
[0047] In some embodiments, the pharmaceutically acceptable cocrystal of the compound of formula (II) is a benzoic acid cocrystal. In some embodiments, the benzoic acid cocrystal is in crystalline form 8, characterized by an XRPD spectrum having peaks at 12.1 ± 0.2, 14.2 ± 0.2, and 16.5 ± 0.2º 2θ. In some embodiments, the benzoic acid cocrystal is characterized by the XRPD morphology shown in FIG29. In some embodiments, the benzoic acid cocrystal is characterized by an endothermic peak at approximately 105 °C, as determined by DSC. In some embodiments, the benzoic acid cocrystal is characterized by the DSC morphology shown in FIG30.
[0048] In some embodiments, the benzoic acid eutectic is characterized by a loss of approximately 18.8% wt between approximately 120°C and 300°C. In some embodiments, the benzoic acid eutectic is characterized by the TG-FTIR morphology shown in FIG31.
[0049] In some embodiments, the crystalline form 8 is characterized by at least two of the following: a) the XRPD pattern shown in FIG29; b) the DSC pattern shown in FIG30; or c) the TG-FTIR pattern shown in FIG31.
[0050] In some embodiments, crystalline form 8 is substantially free of other polymorphic forms. In some embodiments, crystalline form 8 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
[0051] In some embodiments, crystal form 8 has a unit cell that is specified as a monoclinic crystal system. In some embodiments, crystal form 8 has a unit cell with a value of about 10.61070 (10) Å, a value of about 12.39940 (10) Å, and a value of about 24.15170 (10) Å. In some embodiments, crystal form 8 has a unit cell with a volume of about 3114.74 (4) ų.
[0052] In another embodiment, the invention relates to a mixture comprising crystalline form 8 and a second solid form of a compound of formula (II). In some embodiments, the invention relates to a mixture comprising mostly crystalline form 8 compared to other solid forms of a compound of formula (II).
[0053] In some embodiments, the pharmaceutically acceptable cocrystal of the compound of formula (II) is a salicylic acid cocrystal. In some embodiments, the salicylic acid cocrystal is in crystalline form 9, characterized by an XRPD spectrum having peaks at 11.0 ± 0.2, 16.5 ± 0.2, 17.3 ± 0.2, and 25.3 ± 0.2º 2θ. In some embodiments, the salicylic acid cocrystal is characterized by the XRPD morphology shown in FIG33. In some embodiments, the salicylic acid cocrystal is characterized by the 1H NMR spectrum shown in FIG34.
[0054] In some embodiments, the crystalline form 9 is characterized by at least one of the following: a) the XRPD pattern shown in FIG33; or b) the 1H NMR morphology shown in FIG34.
[0055] In some embodiments, crystalline form 9 is substantially free of other polymorphic forms. In some embodiments, crystalline form 9 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
[0056] In some embodiments, crystal form 9 has a unit cell that is specified as a monoclinic crystal system. In some embodiments, crystal form 9 has a unit cell with a value of about 10.8387 (11) Å, a value of about 12.3761 (12) Å, and a value of about 24.242 (2) Å. In some embodiments, crystal form 9 has a unit cell with a volume of about 3173.1 (5) ų.
[0057] In another embodiment, the invention relates to a mixture comprising crystalline form 9 and a second solid form of the compound of formula (II). In some embodiments, the invention relates to a mixture comprising mostly crystalline form 9 compared to other solid forms of the compound of formula (II).
[0058] In some embodiments, the solid form is the solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III): (III), Or a medically acceptable salt.
[0059] In some embodiments, the solid form is the crystalline form of the compound of formula (III). In some embodiments, the crystalline form is its hydrate, anhydrous form, or solvate.
[0060] In some embodiments, the solid form is an amorphous form of the compound of formula (III). In some embodiments, the amorphous form is its hydrate, anhydrous form, or solvate.
[0061] In some embodiments, the solid form of the compound of formula (III) is selected from the group consisting of: a) Crystalline form A1, characterized by XRPD peaks at 16.1 ± 0.2, 16.7 ± 0.2, and 24.8 ± 0.2º 2θ; and b) Crystalline form B1, wherein form B1 is characterized by XRPD spectra with peaks at 12.9 ± 0.2, 14.5 ± 0.2 and 22.6 ± 0.2º 2θ.
[0062] In some embodiments, the solid form of compound (III) is crystalline form A1. In some embodiments, crystalline form A1 is characterized by the XRPD spectrum shown in Figure 11. In some embodiments, crystalline form A1 is characterized by an endothermic peak at approximately 150.5 °C, as determined by DSC. In some embodiments, crystalline form A1 is characterized by the DSC pattern shown in Figure 12. In some embodiments, crystalline form A1 is characterized by a loss of approximately 0.95 wt% between room temperature and approximately 120 °C, as determined by TGA. In some embodiments, crystalline form A1 is characterized by the TGA pattern shown in Figure 12.
[0063] In some embodiments, the crystalline form A1 is characterized by at least two of the following: a) the XRPD pattern shown in FIG11; b) the DSC type shown in FIG12; or c) the TGA type shown in FIG12.
[0064] In some embodiments, crystalline form A1 is substantially free of other polymorphic forms. In some embodiments, crystalline form A1 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
[0065] In some embodiments, crystalline form A1 has a unit cell that is specified as a monoclinic crystal system. In some embodiments, crystalline form A1 has a unit cell with a value of about 12.545 Å, a value of about 8.640 Å, and a value of about 21.660 Å. In some embodiments, crystalline form A1 has a unit cell with a volume of about 2336.13 ų.
[0066] In another embodiment, the invention relates to a mixture comprising a crystalline form A1 and a second solid form of a compound of formula (III). In some embodiments, the invention relates to a mixture comprising mostly crystalline form A1 compared to other solid forms of a compound of formula (III).
[0067] In some embodiments, the solid form of compound (III) is crystalline form B1. In some embodiments, crystalline form B1 is characterized by the XRPD pattern shown in Figure 13. In some embodiments, crystalline form B1 is characterized by an endothermic peak at approximately 161.2 °C, as determined by DSC. In some embodiments, crystalline form B1 is characterized by the DSC pattern shown in Figure 14. In some embodiments, crystalline form B1 is characterized by a loss of approximately 1.58 wt% between room temperature and approximately 120 °C, as determined by TGA. In some embodiments, crystalline form B1 is characterized by the TGA pattern shown in Figure 14.
[0068] In some embodiments, the crystalline form B1 is characterized by at least two of the following: a) the XRPD pattern shown in FIG13; b) the DSC pattern shown in FIG14; or c) the TGA pattern shown in FIG14.
[0069] In some embodiments, crystalline form B1 is substantially free of other polymorphic forms. In some embodiments, crystalline form B1 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.
[0070] In another embodiment, the invention relates to a mixture comprising a crystalline form B1 and a second solid form of a compound of formula (III). In some embodiments, the invention relates to a mixture comprising mostly crystalline form B1 compared to other solid forms of a compound of formula (III).
[0071] In some embodiments, the solid form of the compound of formula (III) is a pharmaceutically acceptable salt or cocrystal of the compound of formula (III).
[0072] In some embodiments, a pharmaceutically acceptable salt or eutectic system is formed between a compound of formula (III) and a pharmaceutically acceptable acid. In some embodiments, the pharmaceutically acceptable acid is selected from 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactobionic acid, gentian acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, propionic acid, etc. The group consisting of diacid, R-mandelic acid, methanesulfonic acid, mucilage, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethoxymaltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, pharmaceutically acceptable acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, pharmaceutically acceptable acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentic acid. In some embodiments, pharmaceutically acceptable acids are benzoic acid derivatives. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxyl groups. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxyl group. In some embodiments, a benzoic acid derivative substituted with one hydroxyl group is salicylic acid. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxyl groups. In some embodiments, a benzoic acid derivative substituted with two hydroxyl groups is gentic acid. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxyl groups. In some embodiments, a benzoic acid derivative substituted with three hydroxyl groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentic acid, and gallic acid. In some embodiments, a pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, a pharmaceutically acceptable acid is gentic acid. In some embodiments, a pharmaceutically acceptable acid is benzoic acid. In some embodiments, a pharmaceutically acceptable acid is salicylic acid. In some embodiments, a pharmaceutically acceptable acid is gallic acid.
[0073] In one embodiment, the present invention relates to a pharmaceutical composition comprising one or more of the solid forms or mixtures described above and one or more pharmaceutically acceptable carriers or diluents.
[0074] In another embodiment, the present invention relates to a solid dosage form comprising one or more of the solid forms or mixtures discussed above.
[0075] In another embodiment, the invention relates to a method for treating cancer, comprising administering to a patient in need one or more of the solid forms, mixtures, pharmaceutical compositions or solid dosage forms discussed above.
[0076] In another embodiment, the invention relates to the use of one or more of the solid forms, mixtures, pharmaceutical compositions or solid dosage forms discussed above for the manufacture of a medicament for the treatment of cancer.
[0077] In another embodiment, the invention relates to one or more of the solid forms, mixtures, pharmaceutical compositions or solid dosage forms discussed above for use in a method of treating cancer.
[0078] In another embodiment, the present invention relates to a method for preparing crystalline form 2 of the gentic acid cocrystal of formula (II) 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine: (II), The method includes: a) Dissolve an appropriate amount of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentic acid in a suitable solvent at room temperature to prepare a solution; b) Add an appropriate amount of suitable antisolvent; c) Seed crystal of gentianic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine in addition to formula (II); d) The suspension obtained by stirring; and e) Collect the solid product produced in step d).
[0079] In some embodiments, the method for preparing crystalline form 2 of the gentianic acid cocrystal of compound (II) further includes adding a suitable antisolvent after step c) and before step d).
[0080] In some embodiments, the suitable solvent is ethyl acetate.
[0081] In some embodiments, the suitable antisolvent is n-heptane.
[0082] In another embodiment, the present invention relates to a method for preparing crystalline form 2 of the gentianic acid cocrystal of formula (II) 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, the method comprising: a) At room temperature, add appropriate amounts of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentic acid to a suitable solvent system to obtain a suspension; b) Stir the suspension from step a); c) Collect the solid product produced in step b).
[0083] In some embodiments, the suitable solvent system is selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.
[0084] In another embodiment, the present invention relates to the crystalline form 2 of the gentianic acid cocrystal of formula (II) of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine prepared by any of the methods described above. Simple Explanation of the Diagram
[0085] [] []
[0086] [Figure 1] is the powder X-ray diffraction pattern ("XRPD") corresponding to crystalline form A. [Figure 2] shows the differential scanning calorimetry (DSC) and pyrolysis gravimetric analysis (TGA) thermograms corresponding to crystalline form A. [Figure 3] is the XRPD pattern corresponding to crystalline form C. [Figure 4] is the XRPD pattern corresponding to crystalline form D. [Figure 5] is the XRPD pattern corresponding to crystalline form E. [Figure 6] shows the DSC and TGA thermograms corresponding to the crystalline form E. [Figure 7] is the XRPD pattern corresponding to crystal form 1. [Figure 8] is the DSC and TGA thermogram corresponding to crystal form 1. [Figure 9] is the XRPD pattern corresponding to crystal form 2. [Figure 10] is the DSC and TGA thermogram corresponding to crystal form 2. [Figure 11] is the XRPD pattern corresponding to the crystalline form A1. [Figure 12] is the DSC and TGA thermograms corresponding to the crystalline form A1. [Figure 13] is the XRPD pattern corresponding to crystalline form B1. [Figure 14] is the DSC and TGA thermogram corresponding to the crystalline form B1. [Figure 15] is the XRPD pattern corresponding to crystal form 3. [Figure 16] is the XRPD pattern corresponding to crystal form 4. [Figure 17] is the XRPD pattern corresponding to crystal form 5. [Figure 18] is the XRPD pattern corresponding to crystal form 6. [Figure 19] is the XRPD pattern corresponding to crystal form 7. [Figure 20] is an asymmetric unit from crystal form A of a single crystal structure. [Figure 21] is an asymmetric unit from crystal form 2 of a single crystal structure. [Figure 22] is an asymmetric unit from the crystal form A1 of the single crystal structure. [Figure 23] shows the plasma concentration versus time curve of crystalline form A in NOD / SCID mice after a dose of 300 mg / kg. [Figure 24] is the plasma concentration versus time curve of crystalline form 2 in NOD / SCID mice after a dose of 300 mg / kg. [Figure 25] is the XRPD pattern corresponding to crystalline form F. [Figure 26] is the DSC thermogram corresponding to the crystalline form F. [Figure 27] is the XRPD pattern corresponding to crystalline form C. [Figure 28] is the Raman spectrum corresponding to crystalline form C. [Figure 29] is the XRPD pattern corresponding to crystal form 8. [Figure 30] is the DSC thermogram corresponding to crystal form 8. [Figure 31] is the TG-FTIR thermogram corresponding to crystal form 8. [Figure 32] is an asymmetric unit from crystal form 8 of a single crystal structure. [Figure 33] is the XRPD pattern corresponding to crystal form 9. [Figure 34] Corresponds to the 1H NMR spectrum of crystalline form 9. [Figure 35] is an asymmetric unit from crystal form 9 of a single crystal structure. [Figure 36] shows the plasma concentration versus time curve of crystalline form 8 in NOD / SCID mice after a dose of 300 mg / kg. [Figure 37] shows the brain and plasma concentrations of crystalline form 2 in NOD / SCID female mice as a function of time after repeated oral doses of 100 and 300 mg / kg QD. [Figure 38] shows the brain and plasma concentrations of crystalline form 2 in male and female SD rats as a function of time after an oral dose of 100 mg / kg. Implementation
[0087] [] Cross-reference to related applications []
[0088] This application claims priority to U.S. Provisional Application No. 63 / 107,765, filed on October 30, 2020, which is incorporated herein by reference in its entirety. I. Definition
[0089] To facilitate understanding of the disclosures presented herein, several terms are defined below.
[0090] Generally, the nomenclature used herein and the laboratory procedures of organic chemistry, medicinal chemistry, and pharmacology described herein are well-known and commonly used in this art. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0091] The instruments and conditions specified under the subheading "Instrument Conditions" at the beginning of the Examples section were used to determine the characterization data for XRPD, DSC and TGA mentioned in this application and the claims.
[0092] Unless otherwise expressly stated herein, the singular forms “a,” “an,” and “the” in this specification and the accompanying claims include plural references. The terms “a” (or “an”) and “one or more” and “at least one” are used interchangeably herein. In some respects, the terms “a” or “an” mean “single.” In other respects, the terms “a” or “an” include “two or more” or “more than one.”
[0093] Furthermore, when used herein, "and / or" should be considered as a specific disclosure of each of the two specified features or components, with or without the other features or components. Thus, as used herein in terms such as "A and / or B," the term "and / or" is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Similarly, as used herein in terms such as "A, B, and / or C," the term "and / or" is intended to cover each of the following states: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0094] The term "compound of formula (I)" refers to compounds encompassed within the following structures: (I), Or a medically acceptable salt, Where R is a C1-3 alkyl group; and X1 and X2 are groups independently chosen from N and C.
[0095] In some embodiments, R may be selected from methyl, ethyl, n-propyl, isopropyl, and cyclopropyl.
[0096] The term "compound of formula (II)" refers to 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine having the following structure: (II).
[0097] The term "compound of formula (III)" refers to 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine having the following structure: (III).
[0098] The term "individual" refers to an animal, including but not limited to primates (such as humans), cattle, sheep, goats, horses, dogs, cats, rabbits, rats, or mice. The terms "individual" and "patient" may be used interchangeably herein, referring to, for example, a mammalian individual, such as a human individual.
[0099] The terms "treat," "treating," and "treatment" are intended to include methods for achieving beneficial or desired clinical outcomes. As used herein, "treatment" encompasses any administration or application of a therapeutic agent for diseases in mammals, including humans. For the purposes of this invention, beneficial or desired clinical outcomes include, but are not limited to, any or more of the following: relief of one or more symptoms, reduction of disease severity, prevention or delay of disease spread (e.g., metastasis), prevention or delay of disease recurrence, delay or slowing of disease progression, improvement of disease state, inhibition of disease or disease progression, inhibition or slowing of disease or its progression, prevention of its development, and remission (partial or complete). "Treatment" also encompasses the pathological outcome of reducing proliferative diseases. The methods provided herein are intended to achieve any or more of these therapeutic outcomes. Consistent with the foregoing, the term "treatment" does not require the complete removal of all aspects of the disease.
[0100] In the context of cancer, the terms "treat," "treating," and "treatment" include, but are not limited to, inhibiting cancer cell growth, inhibiting cancer cell replication, reducing overall tumor burden, and delaying, stopping, or slowing tumor growth, progression, or metastasis.
[0101] As used herein, the terms "cancer" and "tumor" refer to or describe a physiological condition in mammals characterized by unregulated cell growth. These terms encompass both solid and hematologic / lymphomas. Examples of cancer include, but are not limited to, cancers with defects in DNA repair pathways and cancers with defects in homologous recombination (HRD). Additional examples of cancer include, but are not limited to, ovarian cancer, breast cancer (including triple-negative breast cancer), non-small cell lung cancer (NSCLC), and osteosarcoma. The cancer may be BRCA1 and / or BRCA2 wild-type. The cancer may also be BRCA1 and / or BRCA2 mutant. The cancer may further be PARP inhibitor-resistant or refractory cancer, or PARP inhibitor-resistant or refractory BRCA1 or BRCA2 mutant cancer.
[0102] As used herein, the terms "disease" or "disorder" or "symptom" refer to a condition that requires and / or may require treatment and indicate a disorder and / or abnormality, which is generally considered a pathological state or function and may manifest itself in the form of specific signs, symptoms, and / or dysfunctions. As shown below, the compounds of the present invention can be used to treat diseases and disorders, such as proliferative diseases like cancer.
[0103] The "therapeutic effective dose" of a substance can vary depending on factors such as an individual's disease state, age, sex, weight, and the substance's ability to elicit the desired response in that individual. Therapeutic effective dose is also the amount in which any toxic or adverse effects of the substance outweigh the beneficial therapeutic effects. Therapeutic effective doses can be delivered in one or more administrations. Therapeutic effective dose refers to the amount that effectively achieves the desired therapeutic effect at the necessary dose and for the necessary duration.
[0104] The terms "administer", "administer" The terms “administering,” “administration,” and similar terms refer to methods that enable the delivery of therapeutic agents to desired sites of biological action. Administration techniques that can be used with the agents and methods described herein can be found, for example, in Goodman and Gilman, *The Pharmacological Basis of Therapeutics*, current edition; Pergamon; and Remington's, *Pharmaceutical Sciences*, current edition, Mack Publishing Co., Easton, Pa.
[0105] The terms "pharmaceutical formulation" and "pharmaceutical composition" refer to preparations in a form that allows for the bioactivity of the active ingredient and does not contain any additional components that would have unacceptable toxicity to the individual to whom the formulation will be administered. Such formulations may be sterile.
[0106] The terms "pharmaceutically acceptable carrier," "pharmaceutically acceptable excipient," "physiologically acceptable carrier," or "physiologically acceptable excipient" refer to pharmaceutically acceptable materials, compositions, or mediators, such as liquid or solid fillers, diluents, excipients, solvents, or encapsulating materials. A pharmaceutically acceptable carrier is non-toxic to the recipient at the dosage and concentration used and is compatible with the other components of the formulation. A pharmaceutically acceptable carrier is suitable for the formulation used. In one embodiment, each component is "pharmaceutically acceptable" in the sense of compatibility with the other components of the pharmaceutical formulation and is suitable for use in contact with human and animal tissues or organs without excessive toxicity, irritation, allergic reactions, immunogenicity, or other problems or complications, in proportion to a reasonable benefit / risk ratio. See Remington: The Science and Practice of Pharmacy, 21st ed., Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 5th ed., Rowe et al., The Pharmaceutical Press and the American Pharmaceutical Association: 2005; and Handbook of Pharmaceutical Additives, 3rd ed., Ash et al., Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, Gibson, ed., CRC Press LLC: Boca Raton, FL, 2004 (incorporated hereby cited).
[0107] As used herein, the term "about" includes the stated number ± 10%. Therefore, "about 10" means 9 to 11. As will be understood by those skilled in this art, references to a value or parameter of "about" in this document include (and describe) the situation with respect to that value or parameter itself. For example, a description of "about X" includes a description of "X".
[0108] The terms "active ingredient" and "active substance" refer to compounds, alone or in combination with one or more pharmaceutically acceptable excipients, administered to an individual to treat, prevent, or improve one or more symptoms of a disease, condition, or illness. As used herein, "active ingredient" and "active substance" may be optically active isomers of the compounds described herein.
[0109] The terms “drug,” “therapeutic agent,” and “chemotherapy agent” refer to a compound or pharmaceutical composition thereof, administered to an individual to treat, prevent, or improve one or more symptoms of a disease, ailment, or illness.
[0110] The term "solvent" refers to the compound or its salt provided herein, and further includes stoichiometric or non-stoichiometric amounts of solvents bound by non-covalent intermolecular forces. When the solvent is water, the solvate is a hydrate. When the solvent includes ethanol, the compound may be an ethanol solvate.
[0111] As used herein, the term "polycrystalline form" refers to the crystalline form of a compound or its salts, hydrates, or solvates, exhibiting a specific crystalline packing arrangement. All polycrystalline forms have the same elemental composition. As used herein, the term "crystallization" refers to the solid form consisting of an ordered arrangement of structural units. Different crystalline forms of the same compound or its salts, eutectics, hydrates, or solvates arise from different packing arrangements of these molecules in the solid state, resulting in different crystal symmetries and / or unit cell parameters. Different crystalline forms typically have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardness, crystal shapes, optical and electrical properties, stability, and solubility. See, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing, Easton PA, 173 (1990); The United States Pharmacopeia, 23rd edition, 1843-1844 (1995) (incorporated herein by reference).
[0112] X-ray powder diffraction (XRPD) is the most common method for characterizing crystalline forms. The reflected XRPD pattern (peaks, typically expressed as ° 2-θ) is generally considered a fingerprint of a specific crystalline form. The relative intensities of XRPD peaks can vary widely, depending particularly on sample preparation techniques, crystal size distribution, filters, sample preparation procedures, and the specific instrument used. In some cases, new peaks may be observed, or existing peaks may disappear, depending on the instrument type or settings. In some cases, any particular peak in the XRPD pattern may appear as a singlet, doublet, triplet, quartet, or multiple peaks, depending on the instrument type or settings, instrument sensitivity, measurement conditions, and / or the purity of the crystalline form. In some cases, any particular peak in the XRPD may appear symmetrical or asymmetrical, for example, with shoulders. A skilled technician who understands these variations can use XRPD, as well as other known physicochemical techniques, to distinguish or determine the defining characteristics or features of a particular crystalline form.
[0113] When applied to compounds, the term "amorphous" refers to a state in which the material lacks long-range order at the molecular level and, depending on temperature, exhibits physical properties of a solid or liquid. Typically, such materials do not produce distinctive X-ray diffraction patterns and, while exhibiting solid properties, are more formally described as liquids. Upon heating, a change in properties from solid to liquid occurs, characterized by a state change, typically second-order ("glass transition").
[0114] When applied to compounds, the term "anhydrous" refers to a solid state in which the compound does not contain structural water within its crystal lattice.
[0115] Unless otherwise required herein, the terms “comprise”, “comprises” and “comprising” are used in a basic and clear sense, and are to be interpreted inclusively rather than exclusively, and the applicant intends to interpret each of those terms so in interpreting this patent (including the scope of the claims below). II. Solid form
[0116] This invention relates to the solid forms of compounds of formula (I), (II), and (III). For all pharmaceutical compounds and compositions, the chemical and physical properties of compounds of formula (I), (II), and (III) are important for their commercial development. These properties include, but are not limited to: (1) packing properties, such as mole volume, gross density, and hygroscopicity; (2) thermodynamic properties, such as melting temperature, vapor pressure, and solubility; (3) kinetic properties, such as dissolution rate and stability (including stability under ambient conditions, particularly for moisture and under storage conditions); (4) surface properties, such as surface area, wettability, interfacial tension, and shape; (5) mechanical properties, such as hardness, tensile strength, compaction, handling, flow, and blending; and (6) filtration properties. These properties can affect, for example, the processing and storage of these compounds and pharmaceutical compositions containing them.
[0117] Solid-state forms of compounds of formula (I), (II), and (III) may be required, which improve one or more of these properties compared to other solid-state forms of these compounds. Separating pharmaceutically acceptable solid-state forms of these compounds that can be manufactured and formulated on a commercial scale has become a challenge. A. Compound of formula (II)
[0118] In one state, the present invention relates to the solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II), Or a medically acceptable salt.
[0119] In some embodiments, the solid form is an amorphous form of the compound of formula (II). In some embodiments, the amorphous form is its hydrate, anhydrous form, or solvate. In some embodiments, the amorphous form substantially does not contain other polymorphic forms.
[0120] In some embodiments, the invention relates to mixtures comprising a predominantly amorphous form compared to other solid forms of compounds of formula (II). In some embodiments, the amorphous form has a polycrystalline purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0121] In some embodiments, the solid form is the crystalline form of the compound of formula (II). In some embodiments, the crystalline form is its hydrate, anhydrous form, or solvate. In some embodiments, the solvate is a dichloromethane solvate.
[0122] In some embodiments, the solid form of the compound of formula (II) is selected from the group consisting of: a) Crystalline form A, characterized by XRPD spectra with peaks at 14.3 ± 0.2, 21.5 ± 0.2, and 21.8 ± 0.2º 2θ; b) Crystalline form C, characterized by XRPD peaks at 14.2 ± 0.2, 17.0 ± 0.2, and 19.1 ± 0.2º 2θ; c) Crystalline form D, characterized by XRPD spectra with peaks at 13.9 ± 0.2, 15.2 ± 0.2, and 19.3 ± 0.2º 2θ; d) Crystalline form E, characterized by peaks in its XRPD spectrum at 10.6 ± 0.2, 18.7 ± 0.2, and 20.9 ± 0.2º 2θ; and (e) Crystalline form F, wherein form F is characterized by XRPD spectra having peaks at 10.7 ± 0.2, 14.3 ± 0.2 and 21.8 ± 0.2º 2θ.
[0123] In some embodiments, the solid form of the compound of formula (II) is selected from the group consisting of: a) Crystalline form A, characterized by XRPD spectra with peaks at 14.3 ± 0.2, 21.5 ± 0.2, and 21.8 ± 0.2º 2θ; b) Crystalline form C, characterized by XRPD peaks at 14.2 ± 0.2, 17.0 ± 0.2, and 19.1 ± 0.2º 2θ; c) Crystalline form D, characterized by XRPD spectra with peaks at 13.9 ± 0.2, 15.2 ± 0.2, and 19.3 ± 0.2º 2θ; and d) Crystalline form E, wherein form E is characterized by XRPD spectra with peaks at 10.6 ± 0.2, 18.7 ± 0.2, and 20.9 ± 0.2º 2θ.
[0124] In some embodiments, the solid form is a pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). In some embodiments, the pharmaceutically acceptable salt is formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and a pharmaceutically acceptable acid.
[0125] In some embodiments, pharmaceutically acceptable acids are selected from 1-hydroxy-2-naphtholic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactobionic acid, gentian acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, propionic acid, etc. The group consisting of diacid, R-mandelic acid, methanesulfonic acid, mucilage, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethoxymaltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, pharmaceutically acceptable acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, pharmaceutically acceptable acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentic acid. In some embodiments, pharmaceutically acceptable acids are benzoic acid derivatives. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxyl groups. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxyl group. In some embodiments, a benzoic acid derivative substituted with one hydroxyl group is salicylic acid. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxyl groups. In some embodiments, a benzoic acid derivative substituted with two hydroxyl groups is gentianic acid. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxyl groups. In some embodiments, a benzoic acid derivative substituted with three hydroxyl groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentianic acid, and gallic acid. In some embodiments, a pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, a pharmaceutically acceptable acid is hydrobromic acid. In some embodiments, a pharmaceutically acceptable acid is ethanedisulfonic acid. In some embodiments, a pharmaceutically acceptable acid is methanesulfonic acid. In some embodiments, a pharmaceutically acceptable acid is gentianic acid. In some embodiments, a pharmaceutically acceptable acid is benzoic acid. In some embodiments, a pharmaceutically acceptable acid is salicylic acid. In some embodiments, a pharmaceutically acceptable acid is gallic acid.
[0126] In some embodiments, the amorphous form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is a pharmaceutically acceptable salt. In some embodiments, the amorphous form is substantially free of other polymorphic forms. In some embodiments, the amorphous form has a polycrystalline purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0127] In some embodiments, the pharmaceutically acceptable salt crystal form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II).
[0128] In some embodiments, a pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is its hydrate, anhydrous or solvate.
[0129] In some embodiments, a pharmaceutically acceptable salt hydrochloride of formula (II) is used. In some embodiments, the hydrochloride is in crystalline form 1, characterized by an XRPD spectrum having peaks at 12.5 ± 0.2, 22.4 ± 0.2, and 23.9 ± 0.2º 2θ. In some embodiments, the hydrochloride is in crystalline form 1, characterized by the XRPD spectrum shown in FIG7.
[0130] In some embodiments, the hydrochloride salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is in crystalline form 3, characterized by the XRPD spectrum shown in FIG15.
[0131] In some embodiments, the hydrobromide salt of formula (II) is a pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine. In some embodiments, the hydrobromide is in crystalline form 4, characterized by the XRPD pattern shown in FIG16.
[0132] In some embodiments, the hydrobromide of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is in crystalline form 5, characterized by the XRPD spectrum shown in FIG17.
[0133] In some embodiments, the ethane disulfonate salt of formula (II) is a pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine. In some embodiments, the ethane disulfonate salt is in crystalline form 6, characterized by the XRPD pattern shown in FIG18.
[0134] In some embodiments, the methanesulfonate salt of formula (II) is a pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine. In some embodiments, the methanesulfonate salt is in crystalline form 7, characterized by the XRPD pattern shown in FIG19.
[0135] In some embodiments, the solid form is a pharmaceutically acceptable cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and a second pharmaceutically acceptable compound. In some embodiments, the second pharmaceutically acceptable compound is a pharmaceutically acceptable acid. In some embodiments, the pharmaceutically acceptable cocrystal system is formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and a pharmaceutically acceptable acid.
[0136] In some embodiments, pharmaceutically acceptable acids are selected from 1-hydroxy-2-naphtholic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactobionic acid, gentian acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, propionic acid, etc. The group consisting of diacid, R-mandelic acid, methanesulfonic acid, mucilage, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethoxymaltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, pharmaceutically acceptable acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, pharmaceutically acceptable acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentic acid. In some embodiments, pharmaceutically acceptable acids are benzoic acid derivatives. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxyl groups. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxyl group. In some embodiments, a benzoic acid derivative substituted with one hydroxyl group is salicylic acid. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxyl groups. In some embodiments, a benzoic acid derivative substituted with two hydroxyl groups is gentianic acid. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxyl groups. In some embodiments, a benzoic acid derivative substituted with three hydroxyl groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentianic acid, and gallic acid. In some embodiments, a pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, a pharmaceutically acceptable acid is hydrobromic acid. In some embodiments, a pharmaceutically acceptable acid is ethanedisulfonic acid. In some embodiments, a pharmaceutically acceptable acid is methanesulfonic acid. In some embodiments, a pharmaceutically acceptable acid is gentianic acid. In some embodiments, a pharmaceutically acceptable acid is benzoic acid. In some embodiments, a pharmaceutically acceptable acid is salicylic acid. In some embodiments, a pharmaceutically acceptable acid is gallic acid.
[0137] In some embodiments, the pharmaceutically acceptable eutectic system of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is used in its hydrate, anhydrous or solvate form.
[0138] In some embodiments, a pharmaceutically acceptable cocrystal system of gentic acid of formula (II) consisting of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine is used. In some embodiments, the gentic acid cocrystal is in crystalline form 2, characterized by XRPD spectra having peaks at 16.6 ± 0.2, 18.7 ± 0.2, and 22.5 ± 0.2º 2θ.
[0139] In some embodiments, a pharmaceutically acceptable eutectic system of benzoic acid of formula (II) consisting of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine is used. In some embodiments, the benzoic acid eutectic is in crystalline form 8, characterized by XRPD spectra having peaks at 12.1 ± 0.2, 14.2 ± 0.2, and 16.5 ± 0.2º 2θ. a) In some embodiments, a pharmaceutically acceptable cocrystal system of salicylic acid of formula (II) consisting of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine. In some embodiments, the salicylic acid cocrystal is in crystalline form 9, characterized by substantially the XRPD pattern shown in FIG33.
[0140] The following section discusses the solid forms of compounds of formula (II), the characteristics of which have been identified and selected. 1. Crystallization form A
[0141] In one state, the present invention relates to the crystalline form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II).
[0142] In some embodiments, the crystalline form is A-series 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine hydrate.
[0143] In some embodiments, the melting point of crystalline form A is about 165°C.
[0144] In some embodiments, crystalline form A is characterized by having peaks at 14.3 ± 0.2, 21.5 ± 0.2, and 21.8 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, crystalline form A is characterized by having peaks at 7.1 ± 0.2, 14.3 ± 0.2, 21.5 ± 0.2, and 21.8 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In yet another embodiment, crystalline form A is characterized by having peaks at 7.1 ± 0.2, 14.3 ± 0.2, 19.1 ± 0.2, 21.5 ± 0.2, and 21.8 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, the crystalline form A is characterized by having peaks at 7.1 ± 0.2, 14.3 ± 0.2, 15.2 ± 0.2, 19.1 ± 0.2, 21.5 ± 0.2 and 21.8 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation.
[0145] In some embodiments, crystalline form A is characterized by an XRPD pattern substantially as shown in Figure 1.
[0146] In some embodiments, crystalline form A is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 1 below.
[0147] In some embodiments, crystalline form A is characterized by an endothermic peak at about 162°C to about 168°C, or about 163°C to about 167°C, or about 164°C to about 166°C, as determined by DSC. In some embodiments, crystalline form A is characterized by an endothermic peak at about 165°C, as determined by DSC.
[0148] In some embodiments, crystalline form A is characterized by a DSC morphology as shown in FIG2.
[0149] In some embodiments, crystalline form A is characterized by a loss of about 0.88 wt% to about 0.98 wt% between room temperature and about 150°C. In some embodiments, crystalline form A is characterized by a loss of about 0.90 wt% to about 0.96 wt% between room temperature and about 150°C. In some embodiments, crystalline form A is characterized by a loss of about 0.93 wt% between room temperature and about 150°C.
[0150] In some embodiments, crystalline form A is characterized by being substantially the TGA morphology as shown in Figure 2.
[0151] In some embodiments, crystalline form A is characterized by at least two of the following: a) the XRPD pattern shown in FIG1; b) the DSC pattern shown in FIG2; or c) the TGA pattern shown in FIG2.
[0152] In some embodiments, crystal form A has a unit cell that is specified as a monoclinic crystal system.
[0153] In some embodiments, crystalline form A has a unit cell with a value of about 12.054 Å, a value of about 8.775 Å, and a value of about 24.837 Å. In other embodiments, form A has a unit cell with a volume of about 2603.68 ų.
[0154] In some embodiments, crystalline form A substantially does not contain other polymorphic forms. In some embodiments, crystalline form A has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%. In some embodiments, crystalline form A has a polymorphic purity of at least 80%.
[0155] In another embodiment, the present invention relates to a mixture comprising a crystalline form A and a second solid form of a compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form C, or crystalline form D, or crystalline form E, or crystalline form F, or crystalline form 1, or crystalline form 2, or crystalline form 8, or crystalline form 9. In some embodiments, the second solid form of the compound of formula (II) is crystalline form C, or crystalline form D, or crystalline form F, or crystalline form 1, or crystalline form 2.
[0156] In some embodiments, the invention relates to mixtures comprising a majority of crystalline form A compared to other solid forms of the compound of formula (II). 2. Crystallization form C
[0157] In one state, the present invention relates to the crystalline form C of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II).
[0158] In some embodiments, crystalline form C is an anhydrous form.
[0159] In some embodiments, crystalline form C is characterized by having peaks at 14.2 ± 0.2, 17.0 ± 0.2, and 19.1 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, crystalline form C is characterized by having peaks at 14.2 ± 0.2, 17.0 ± 0.2, 19.1 ± 0.2, and 21.5 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In yet another embodiment, crystalline form C is characterized by having peaks at 14.2 ± 0.2, 17.0 ± 0.2, 19.1 ± 0.2, 19.8 ± 0.2, and 21.5 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, the crystalline form C is characterized by having peaks at 14.2 ± 0.2, 17.0 ± 0.2, 19.1 ± 0.2, 19.8 ± 0.2, 21.5 ± 0.2, and 21.8 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation.
[0160] In some embodiments, the crystalline form C is characterized by an XRPD pattern substantially as shown in Figure 3.
[0161] In some embodiments, the crystalline form C is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 2 below.
[0162] In some embodiments, crystalline form C substantially does not contain other polymorphic forms. In some embodiments, crystalline form C has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0163] In another embodiment, the present invention relates to a mixture comprising a crystalline form C and a second solid form of a compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form D, or crystalline form E, or crystalline form F, or crystalline form 1, or crystalline form 2, or crystalline form 8, or crystalline form 9. In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form D, or crystalline form E, or crystalline form 1, or crystalline form 2.
[0164] In some embodiments, the invention relates to mixtures comprising a majority of crystalline form C compared to other solid forms of compounds of formula (II). 3. Crystallization form D
[0165] In one state, the present invention relates to the crystalline form D of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II).
[0166] In some embodiments, the crystalline form D is an anhydrous substance.
[0167] In some embodiments, crystalline form D is characterized by having peaks at 13.9 ± 0.2, 15.2 ± 0.2, and 19.3 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, crystalline form D is characterized by having peaks at 13.9 ± 0.2, 15.2 ± 0.2, 16.4 ± 0.2, and 19.3 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In yet another embodiment, crystalline form D is characterized by having peaks at 13.9 ± 0.2, 15.2 ± 0.2, 16.4 ± 0.2, 19.3 ± 0.2, and 20.9 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, the crystalline form D is characterized by having peaks at 13.9 ± 0.2, 15.2 ± 0.2, 16.4 ± 0.2, 19.3 ± 0.2, 20.9 ± 0.2 and 21.6 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation.
[0168] In some embodiments, the crystalline form D is characterized by an XRPD pattern substantially as shown in Figure 4.
[0169] In some embodiments, the crystalline form D is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 2 below.
[0170] In some embodiments, crystalline form D substantially does not contain other polymorphic forms. In some embodiments, crystalline form D has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0171] In another embodiment, the present invention relates to a mixture comprising a crystalline form D and a second solid form of a compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form E, or crystalline form F, or crystalline form 1, or crystalline form 2, or crystalline form 8, or crystalline form 9. In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form E, or crystalline form 1, or crystalline form 2.
[0172] In some embodiments, the invention relates to mixtures comprising a majority of crystalline form D compared to other solid forms of the compound of formula (II). 4. Crystallization form E
[0173] In one state, the present invention relates to the crystalline form E of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II).
[0174] In some embodiments, crystalline form E is a solvate. In some embodiments, crystalline form E is a dichloromethane solvate.
[0175] In some embodiments, the melting point of crystalline form E is about 107°C.
[0176] In some embodiments, crystalline form E is characterized by having peaks at 10.6 ± 0.2, 18.7 ± 0.2, and 20.9 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, crystalline form E is characterized by having peaks at 10.6 ± 0.2, 18.7 ± 0.2, 20.9 ± 0.2, and 21.2 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In yet another embodiment, crystalline form E is characterized by having peaks at 10.6 ± 0.2, 16.4 ± 0.2, 18.7 ± 0.2, 20.9 ± 0.2, and 21.2 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, the crystalline form E is characterized by having peaks at 10.6 ± 0.2, 16.4 ± 0.2, 18.7 ± 0.2, 20.9 ± 0.2, 21.2 ± 0.2 and 23.9 ± 0.2º 2θ in the XRPD spectrum when measured by Cu Kα radiation.
[0177] In some embodiments, the crystalline form E is characterized by an XRPD pattern substantially as shown in FIG5.
[0178] In some embodiments, the crystalline form E is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 4 below.
[0179] In some embodiments, crystalline form E is characterized by an endothermic peak at about 102°C to about 112°C, or about 104°C to about 110°C, or about 106°C to about 108°C, as determined by DSC. In some embodiments, crystalline form E is characterized by an endothermic peak at about 107°C, as determined by DSC.
[0180] In some embodiments, the crystalline form E is characterized by a DSC morphology as shown in FIG6.
[0181] In some embodiments, crystalline form E is characterized by a loss of about 13.0 wt% to about 14.0 wt% between room temperature and about 200°C. In some embodiments, crystalline form E is characterized by a loss of about 13.2 wt% to about 13.8 wt% between room temperature and about 200°C. In some embodiments, crystalline form E is characterized by a loss of about 13.5 wt% between room temperature and about 200°C.
[0182] In some embodiments, the crystalline form E is characterized by being substantially the TGA morphology as shown in FIG6.
[0183] In some embodiments, the crystalline form E is characterized by at least two of the following: a) the XRPD pattern shown in FIG5; b) the DSC pattern shown in FIG6; or c) the TGA pattern shown in FIG6.
[0184] In some embodiments, crystalline form E is substantially free of other polymorphic forms. In some embodiments, crystalline form E has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0185] In another embodiment, the present invention relates to a mixture comprising a crystalline form E and a second solid form of a compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form F, or crystalline form 1, or crystalline form 2, or crystalline form 8, or crystalline form 9. In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form 1, or crystalline form 2.
[0186] In some embodiments, the invention relates to mixtures comprising a majority of crystalline form E compared to other solid forms of compounds of formula (II). 5. Crystallization form F
[0187] In one state, the present invention relates to the crystalline form F of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II).
[0188] In some embodiments, the crystalline form F is an anhydrous substance.
[0189] In some embodiments, crystalline form F is characterized by having peaks at 10.7 ± 0.2, 14.3 ± 0.2, and 21.8 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, crystalline form F is characterized by having peaks at 10.7 ± 0.2, 14.3 ± 0.2, 21.5 ± 0.2, and 21.8 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In yet another embodiment, crystalline form F is characterized by having peaks at 10.7 ± 0.2, 14.3 ± 0.2, 15.8 ± 0.2, 21.5 ± 0.2, and 21.8 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, the crystalline form F is characterized by having peaks at 10.7 ± 0.2, 14.3 ± 0.2, 15.8 ± 0.2, 21.5 ± 0.2, 21.8 ± 0.2 and 25.0 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation.
[0190] In some embodiments, the crystalline form F is characterized by an XRPD pattern substantially as shown in FIG25.
[0191] In some embodiments, the crystalline form F is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 5 below.
[0192] In some embodiments, crystalline form F is characterized by an endothermic peak at about 153°C to about 160°C, or about 154°C to about 159°C, or about 155°C to about 158°C, as determined by DSC. In some embodiments, crystalline form F is characterized by an endothermic peak at about 157°C, as determined by DSC.
[0193] In some embodiments, the crystalline form F is characterized by being substantially the DSC type as shown in FIG26.
[0194] In some embodiments, the crystalline form F is characterized by at least one of the following: a) the XRPD pattern shown in Figure 25; or b) the DSC pattern shown in Figure 26.
[0195] In some embodiments, crystalline form F substantially does not contain other polymorphic forms. In some embodiments, crystalline form F has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0196] In another embodiment, the present invention relates to a mixture comprising a crystalline form F and a second solid form of a compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form 1, or crystalline form 2, or crystalline form 8, or crystalline form 9.
[0197] In some embodiments, the invention relates to mixtures comprising a majority of the crystalline form F compared to other solid forms of the compound of formula (II). 6. Crystallization Form 1
[0198] In one state, the present invention relates to the crystalline form 1 of the hydrochloride salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II).
[0199] In some embodiments, the crystalline form is 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride hydrate.
[0200] In some embodiments, the melting point of crystalline form 1 is from about 140°C to about 145°C. In some embodiments, the melting point of crystalline form 1 is from about 140°C to about 143°C. In some embodiments, the melting point of crystalline form 1 is about 140.8°C.
[0201] In some embodiments, crystal form 1 is characterized by having peaks at 12.5 ± 0.2, 22.4 ± 0.2, and 23.9 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, crystal form 1 is characterized by having peaks at 12.5 ± 0.2, 17.2 ± 0.2, 22.4 ± 0.2, and 23.9 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In yet another embodiment, crystal form 1 is characterized by having peaks at 12.5 ± 0.2, 17.2 ± 0.2, 19.7 ± 0.2, 22.4 ± 0.2, and 23.9 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, the crystalline form 1 is characterized by having peaks at 12.5 ± 0.2, 17.2 ± 0.2, 19.7 ± 0.2, 22.4 ± 0.2, 23.1 ± 0.2 and 23.9 ± 0.2º 2θ in the XRPD spectrum when measured by Cu Kα radiation.
[0202] In some embodiments, crystalline form 1 is characterized by an XRPD pattern substantially as shown in FIG7.
[0203] In some embodiments, crystalline form 1 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 6 below.
[0204] In some embodiments, crystalline form 1 is characterized by an endothermic peak at about 136°C to about 146°C, or about 138°C to about 144°C, or about 140°C to about 143°C, as determined by DSC. In some embodiments, crystalline form 1 is characterized by an endothermic peak at about 142.1°C, as determined by DSC.
[0205] In some embodiments, crystalline form 1 is characterized by being substantially the DSC type as shown in FIG8.
[0206] In some embodiments, crystalline form 1 is characterized by a loss of about 3.0 wt% to about 5.0 wt% between about 30°C and about 100°C. In some embodiments, crystalline form 1 is characterized by a loss of about 3.5 wt% to about 4.5 wt% between about 30°C and about 100°C. In some embodiments, crystalline form 1 is characterized by a loss of about 4.04 wt% between about 30°C and about 100°C.
[0207] In some embodiments, the crystalline form 1 is characterized by being substantially the TGA morphology as shown in FIG8.
[0208] In some embodiments, crystalline form 1 is characterized by a loss of about 12.0 wt% to about 14.0 wt% between room temperature and about 180°C. In some embodiments, crystalline form 1 is characterized by a loss of about 12.8 wt% to about 13.4 wt% between room temperature and about 180°C. In some embodiments, crystalline form 1 is characterized by a loss of about 13.13 wt% between room temperature and about 180°C.
[0209] In some embodiments, the crystalline form 1 is characterized by at least two of the following: a) the XRPD pattern shown in FIG7; b) the DSC type shown in FIG8; or c) the TGA type shown in FIG8.
[0210] In some embodiments, crystalline form 1 is substantially free of other polymorphic forms. In some embodiments, crystalline form 1 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0211] In another embodiment, the present invention relates to a mixture comprising a crystalline form 1 and a second solid form of a compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form F, or crystalline form 2, or crystalline form 8, or crystalline form 9. In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form 2.
[0212] In some embodiments, the invention relates to mixtures comprising a majority of crystalline form 1 compared to other solid forms of compounds of formula (II). 7. Crystallization Form 2
[0213] In one state sample, the present invention relates to crystalline form 2 of the gentic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II).
[0214] In some embodiments, crystalline form 2 is an anhydrous form.
[0215] In some embodiments, the melting point of crystalline form 2 is from about 184°C to about 190°C. In some embodiments, the melting point of crystalline form 2 is from about 186°C to about 188°C. In some embodiments, the melting point of crystalline form 2 is about 187°C.
[0216] In some embodiments, crystalline form 2 is characterized by having peaks at 16.6 ± 0.2, 18.7 ± 0.2, and 22.5 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, crystalline form 2 is characterized by having peaks at 16.6 ± 0.2, 18.7 ± 0.2, 22.3 ± 0.2, and 22.5 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In yet another embodiment, crystalline form 2 is characterized by having peaks at 16.6 ± 0.2, 18.7 ± 0.2, 22.3 ± 0.2, 22.5 ± 0.2, and 26.0 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, the crystalline form 2 is characterized by having peaks at 16.6 ± 0.2, 18.7 ± 0.2, 20.8 ± 0.2, 22.3 ± 0.2, 22.5 ± 0.2 and 26.0 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation.
[0217] In some embodiments, crystalline form 2 is characterized by an XRPD pattern substantially as shown in FIG9.
[0218] In some embodiments, the crystalline form 2 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 7 below.
[0219] In some embodiments, crystalline form 2 is characterized by an endothermic peak at about 181°C to about 191°C, or about 183°C to about 189°C, or about 185°C to about 187°C, as determined by DSC. In some embodiments, crystalline form 2 is characterized by an endothermic peak at about 186.0°C, as determined by DSC.
[0220] In some embodiments, the crystalline form 2 is characterized by a DSC morphology as shown in FIG10.
[0221] In some embodiments, crystalline form 2 is characterized by a loss of about 2.5 wt% to about 3.5 wt% between room temperature and about 170°C. In some embodiments, crystalline form 2 is characterized by a loss of about 3.0 wt% to about 3.4 wt% between room temperature and about 170°C. In some embodiments, crystalline form 2 is characterized by a loss of about 3.17 wt% between room temperature and about 170°C.
[0222] In some embodiments, the crystalline form 2 is characterized by being substantially the TGA morphology as shown in FIG10.
[0223] In some embodiments, the crystalline form 2 is characterized by at least two of the following: a) the XRPD pattern shown in FIG9; b) the DSC pattern shown in FIG10; or c) the TGA pattern shown in FIG10.
[0224] In some embodiments, crystal form 2 has a unit cell that is specified as a monoclinic crystal system.
[0225] In some embodiments, crystalline form 2 has a unit cell with a value of about 11.113 Å, a value of about 12.356 Å, and a value of about 24.048 Å. In other embodiments, form 2 has a unit cell with a volume of about 3223.93 ų.
[0226] The unit cell parameters for crystal form 2 are as follows:
[0227] In some embodiments, crystalline form 2 is substantially free of other polymorphic forms. In some embodiments, crystalline form 2 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0228] In another embodiment, the present invention relates to a mixture comprising crystalline form 2 and a second solid form of a compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form F, or crystalline form 1, or crystalline form 8, or crystalline form 9. In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form 1.
[0229] In some embodiments, the invention relates to mixtures comprising a majority of crystalline form 2 compared to other solid forms of the compound of formula (II).
[0230] Compared to the free base form, crystalline form 2 exhibits unexpected chemical and physical properties as well as favorable bioavailability. Specifically, as shown in Figure 21, 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentic acid of formula (II) exhibit significant hydrogen bonding interactions, but also show interactions between weak bases and weak acids.
[0231] Furthermore, as shown in Example 14, crystalline form 2 unexpectedly exhibits increased oral exposure levels in mice compared to other solid forms of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). For example, as shown in Example 14, in some embodiments, crystalline form 2 (gentianic acid cocrystal) exhibits higher exposure levels at approximately 300 mg / kg than crystalline form A (free base). 8. Crystallization Form 3
[0232] In another embodiment, the present invention relates to crystalline form 3 of the hydrochloride salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II).
[0233] In some embodiments, crystalline form 3 is characterized by an XRPD pattern substantially as shown in FIG15. 9. Crystallization Form 4
[0234] In another embodiment, the present invention relates to crystalline form 4 of the hydrobromide of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II).
[0235] In some embodiments, crystalline form 4 is characterized by an XRPD pattern substantially as shown in FIG16. 10. Crystallization Form 5
[0236] In another embodiment, the present invention relates to the crystalline form 5 of the hydrobromide of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II).
[0237] In some embodiments, crystalline form 5 is characterized by an XRPD pattern substantially as shown in FIG17. 11. Crystallization Form 6
[0238] In another embodiment, the present invention relates to the crystalline form 6 of the ethane disulfonate of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine: (II).
[0239] In some embodiments, crystalline form 6 is characterized by an XRPD pattern substantially as shown in FIG18. 12. Crystallization Form 7
[0240] In another embodiment, the present invention relates to the crystalline form 7 of the methanesulfonate of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II).
[0241] In some embodiments, crystalline form 7 is characterized by an XRPD pattern substantially as shown in FIG19. 13. Crystallization Form 8
[0242] In one state, the present invention relates to the crystalline form 8 of the benzoic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II).
[0243] In some embodiments, crystalline form 8 is an anhydrous form.
[0244] In some embodiments, the melting point of crystalline form 8 is from about 100°C to about 110°C. In some embodiments, the melting point of crystalline form 8 is from about 102°C to about 108°C. In some embodiments, the melting point of crystalline form 8 is about 105°C.
[0245] In some embodiments, crystalline form 8 is characterized by having peaks at 12.1 ± 0.2, 14.2 ± 0.2, and 16.5 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, crystalline form 8 is characterized by having peaks at 12.1 ± 0.2, 16.5 ± 0.2, 19.0 ± 0.2, and 21.0 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In yet another embodiment, crystalline form 8 is characterized by having peaks at 12.1 ± 0.2, 14.2 ± 0.2, 16.5 ± 0.2, and 21.0 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, the crystalline form 8 is characterized by having peaks at 12.1 ± 0.2, 16.5 ± 0.2, 21.0 ± 0.2, 23.0 ± 0.2 and 25.7 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation.
[0246] In some embodiments, crystalline form 8 is characterized by an XRPD pattern substantially as shown in FIG29.
[0247] In some embodiments, the crystalline form 8 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 8 below.
[0248] In some embodiments, crystalline form 8 is characterized by an endothermic peak at about 100°C to about 110°C, or about 102°C to about 108°C, or about 104°C to about 106°C, as determined by DSC. In some embodiments, crystalline form 8 is characterized by an endothermic peak at about 105.3°C, as determined by DSC.
[0249] In some embodiments, the crystalline form 8 is characterized by a DSC morphology as shown in FIG30.
[0250] In some embodiments, crystalline form 8 is characterized by a loss of about 14 wt% to about 24 wt% between about 120°C and about 300°C. In some embodiments, crystalline form 8 is characterized by a loss of about 16 wt% to about 20 wt% between about 120°C and about 300°C. In some embodiments, crystalline form 8 is characterized by a loss of about 18 wt% to about 19 wt% between about 120°C and about 300°C. In some embodiments, crystalline form 8 is characterized by a loss of about 18.8 wt% between about 120°C and about 300°C.
[0251] In some embodiments, the crystalline form 8 is characterized by being substantially the TG-FTIR type as shown in FIG31.
[0252] In some embodiments, the crystalline form 8 is characterized by at least two of the following: a) the XRPD pattern shown in FIG29; b) the DSC pattern shown in FIG30; or c) the TG-FTIR pattern shown in FIG31.
[0253] In some embodiments, crystal form 8 has a unit cell that is specified as a monoclinic crystal system.
[0254] In some embodiments, crystalline form 8 has a unit cell with a value of about 10.61070 (10) Å, a value of about 12.39940 (10) Å, and a value of about 24.15170 (10) Å. In other embodiments, form 8 has a unit cell with a volume of about 3114.74 (4) ų.
[0255] The unit cell parameters for crystal form 8 are as follows:
[0256] In some embodiments, crystalline form 8 is substantially free of other polymorphic forms. In some embodiments, crystalline form 8 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0257] In another embodiment, the present invention relates to a mixture comprising crystalline form 8 and a second solid form of a compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form F, or crystalline form 1, or crystalline form 2, or crystalline form 9.
[0258] In some embodiments, the invention relates to mixtures comprising mostly crystalline form 8 compared to other solid forms of the compound of formula (II). 14. Crystallization Form 9
[0259] In one state, the present invention relates to the crystalline form 9 of the salicylic acid co-crystal of formula (II) 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine: (II).
[0260] In some embodiments, crystalline form 9 is an anhydrous form.
[0261] In some embodiments, the crystalline form 9 is characterized by having peaks at 11.0 ± 0.2, 16.5 ± 0.2, and 25.3 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, the crystalline form 9 is characterized by having peaks at 11.0 ± 0.2, 16.5 ± 0.2, 17.3 ± 0.2, and 25.3 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation.
[0262] In some embodiments, crystalline form 9 is characterized by an XRPD pattern substantially as shown in FIG33.
[0263] In some embodiments, the crystalline form 9 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 9 below.
[0264] In some embodiments, the crystalline form 9 is characterized by a substantially 1H NMR morphology as shown in FIG34.
[0265] In some embodiments, the crystalline form 9 is characterized by at least one of the following: a) the XRPD pattern shown in FIG33; or b) the 1H NMR morphology shown in FIG34.
[0266] In some embodiments, crystal form 9 has a unit cell that is specified as a monoclinic crystal system.
[0267] In some embodiments, crystalline form 9 has a unit cell with a value of about 10.8387 (11) Å, a value of about 12.3761 (12) Å, and a value of about 24.242 (2) Å. In other embodiments, form 9 has a unit cell with a volume of about 3173.1 (5) ų.
[0268] The unit cell parameters for crystal form 9 are as follows:
[0269] In some embodiments, crystalline form 9 is substantially free of other polymorphic forms. In some embodiments, crystalline form 9 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0270] In another embodiment, the present invention relates to a mixture comprising crystalline form 9 and a second solid form of a compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form F, or crystalline form 1, or crystalline form 2, or crystalline form 8.
[0271] In some embodiments, the invention relates to mixtures comprising a majority of crystalline form 9 compared to other solid forms of compounds of formula (II). B. Compounds of Formula (III)
[0272] In one state, the present invention relates to the solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III): (III), Or a medically acceptable salt.
[0273] In some embodiments, the solid form is an amorphous form of the compound of formula (III). In some embodiments, the amorphous form is its hydrate, anhydrous form, or solvate. In some embodiments, the amorphous form is substantially free of other polymorphic forms. In some embodiments, the amorphous form has a polycrystalline purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0274] In some embodiments, the invention relates to mixtures comprising a majority of the amorphous form compared to other solid forms of the compound of formula (III).
[0275] In some embodiments, the solid form is the crystalline form of the compound of formula (III). In some embodiments, the crystalline form is its hydrate, anhydrous form, or solvate.
[0276] In some embodiments, the solid form of the compound of formula (III) is selected from the group consisting of: a) Crystalline form A1, characterized by XRPD peaks at 16.1 ± 0.2, 16.7 ± 0.2, and 24.8 ± 0.2º 2θ; and b) Crystalline form B1, wherein form B1 is characterized by XRPD spectra with peaks at 12.9 ± 0.2, 14.5 ± 0.2 and 22.6 ± 0.2º 2θ.
[0277] In some embodiments, the solid form is a pharmaceutically acceptable salt or cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III). In some embodiments, the pharmaceutically acceptable salt or cocrystal system is formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) and a pharmaceutically acceptable acid.
[0278] In some embodiments, pharmaceutically acceptable acids are selected from 1-hydroxy-2-naphtholic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactobionic acid, gentian acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, propionic acid, etc. The group consisting of diacid, R-mandelic acid, methanesulfonic acid, mucilage, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethoxymaltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, pharmaceutically acceptable acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, pharmaceutically acceptable acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentic acid. In some embodiments, pharmaceutically acceptable acids are benzoic acid derivatives. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxyl groups. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxyl group. In some embodiments, a benzoic acid derivative substituted with one hydroxyl group is salicylic acid. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxyl groups. In some embodiments, a benzoic acid derivative substituted with two hydroxyl groups is gentic acid. In some embodiments, a pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxyl groups. In some embodiments, a benzoic acid derivative substituted with three hydroxyl groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentic acid, and gallic acid. In some embodiments, a pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, a pharmaceutically acceptable acid is gentic acid. In some embodiments, a pharmaceutically acceptable acid is benzoic acid. In some embodiments, a pharmaceutically acceptable acid is salicylic acid. In some embodiments, a pharmaceutically acceptable acid is gallic acid.
[0279] In some embodiments, the amorphous form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) is a pharmaceutically acceptable salt. In some embodiments, the amorphous form is substantially free of other polymorphic forms. In some embodiments, the amorphous form has a polycrystalline purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0280] In some embodiments, the pharmaceutically acceptable salt or eutectic crystal form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) is used.
[0281] In some embodiments, a pharmaceutically acceptable salt or eutectic system of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) is used as its hydrate, anhydrous form or solvate.
[0282] The following sections discuss the solid forms of compounds of formula (III), the characteristics of which have been identified and selected. 1. Crystalline form A1
[0283] In one state, the present invention relates to the crystalline form A1 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III): (III).
[0284] In some embodiments, the crystalline form A1 is an anhydrous substance.
[0285] In some embodiments, the melting point of crystalline form A1 is from about 148°C to about 152°C. In some embodiments, the melting point of crystalline form A1 is from about 150°C to about 152°C. In some embodiments, the melting point of crystalline form A1 is about 150.5°C.
[0286] In some embodiments, crystalline form A1 is characterized by having peaks at 16.1 ± 0.2, 16.7 ± 0.2, and 24.8 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, crystalline form A1 is characterized by having peaks at 16.1 ± 0.2, 16.7 ± 0.2, 22.2 ± 0.2, and 24.8 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In yet another embodiment, crystalline form A1 is characterized by having peaks at 16.1 ± 0.2, 16.7 ± 0.2, 20.6 ± 0.2, 22.2 ± 0.2, and 24.8 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, the crystalline form A1 is characterized by having peaks at 8.1 ± 0.2, 16.1 ± 0.2, 16.7 ± 0.2, 20.6 ± 0.2, 22.2 ± 0.2 and 24.8 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation.
[0287] In some embodiments, the crystalline form A1 is characterized by an XRPD pattern substantially as shown in FIG11.
[0288] In some embodiments, the crystalline form A1 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 10 below.
[0289] In some embodiments, crystalline form A1 is characterized by an endothermic peak at about 146°C to about 154°C, or about 148°C to about 152°C, or about 150°C to about 152°C, as determined by DSC. In some embodiments, crystalline form A1 is characterized by an endothermic peak at about 150.5°C, as determined by DSC.
[0290] In some embodiments, the crystalline form A1 is characterized by a DSC morphology as shown in FIG12.
[0291] In some embodiments, the crystalline form A1 is characterized by a loss of about 0.90 wt% to about 1.0 wt% between room temperature and about 120°C. In some embodiments, the crystalline form A1 is characterized by a loss of about 0.92 wt% to about 0.98 wt% between room temperature and about 120°C. In some embodiments, the crystalline form A1 is characterized by a loss of about 0.95 wt% between room temperature and about 120°C.
[0292] In some embodiments, the crystalline form A1 is characterized by being substantially the TGA morphology as shown in FIG12.
[0293] In some embodiments, the crystalline form A1 is characterized by at least two of the following: a) the XRPD pattern shown in FIG11; b) the DSC type shown in FIG12; or c) the TGA type shown in FIG12.
[0294] In some embodiments, the crystalline form A1 has a unit cell that is specified as a monoclinic crystal system.
[0295] In some embodiments, crystalline form A1 has a unit cell with a value of about 12.545 Å, a value of about 8.640 Å, and a value of about 21.660 Å. In other embodiments, form A has a unit cell with a volume of about 2336.13 ų.
[0296] The unit cell parameters of crystal form A1 are as follows:
[0297] In some embodiments, crystalline form A1 substantially contains no other polymorphic forms. In some embodiments, crystalline form A1 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%. In some embodiments, crystalline form A1 has a polymorphic purity of at least 80%.
[0298] In another embodiment, the invention relates to a mixture comprising a crystalline form A1 and a second solid form of a compound of formula (III). In some embodiments, the second solid form of the compound of formula (III) is the crystalline form B1.
[0299] In some embodiments, the invention relates to mixtures comprising a majority of the crystalline form A1 compared to other solid forms of the compound of formula (III). 2. Crystalline form B1
[0300] In one state, the present invention relates to the crystalline form B1 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III): (III).
[0301] In some embodiments, crystalline form B1 is an anhydrous form.
[0302] In some embodiments, the melting point of crystalline form B1 is from about 160°C to about 164°C. In some embodiments, the melting point of crystalline form B1 is from about 161°C to about 163°C. In some embodiments, the melting point of crystalline form B1 is about 162.1°C.
[0303] In some embodiments, crystalline form B1 is characterized by having peaks at 12.9 ± 0.2, 14.5 ± 0.2, and 22.6 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, crystalline form B1 is characterized by having peaks at 12.9 ± 0.2, 14.5 ± 0.2, 16.7 ± 0.2, and 22.6 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In yet another embodiment, crystalline form B1 is characterized by having peaks at 12.9 ± 0.2, 14.5 ± 0.2, 16.7 ± 0.2, 22.6 ± 0.2, and 24.2 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation. In another embodiment, the crystalline form B1 is characterized by having peaks at 12.9 ± 0.2, 14.5 ± 0.2, 16.7 ± 0.2, 20.7 ± 0.2, 22.6 ± 0.2, and 24.2 ± 0.2º 2θ in its XRPD spectrum when measured by Cu Kα radiation.
[0304] In some embodiments, the crystalline form B1 is characterized by an XRPD pattern substantially as shown in FIG13.
[0305] In some embodiments, crystalline form B1 is characterized by three or more, four or more, five or more, or six or more XRPD peaks listed in Table 11 below.
[0306] In some embodiments, crystalline form B1 is characterized by an endothermic peak at about 156°C to about 166°C, or about 159°C to about 163°C, or about 160°C to about 162°C, as determined by DSC. In some embodiments, crystalline form B1 is characterized by an endothermic peak at about 161.2°C, as determined by DSC.
[0307] In some embodiments, the crystalline form B1 is characterized by a DSC morphology as shown in FIG14.
[0308] In some embodiments, crystalline form B1 is characterized by a loss of about 1.0 wt% to about 2.0 wt% between room temperature and about 120°C. In some embodiments, crystalline form B1 is characterized by a loss of about 1.2 wt% to about 1.8 wt% between room temperature and about 120°C. In some embodiments, crystalline form B1 is characterized by a loss of about 1.58 wt% between room temperature and about 120°C.
[0309] In some embodiments, the crystalline form B1 is characterized by being substantially the TGA morphology as shown in FIG14.
[0310] In some embodiments, the crystalline form B1 is characterized by at least two of the following: a) the XRPD pattern shown in FIG13; b) the DSC pattern shown in FIG14; or c) the TGA pattern shown in FIG14.
[0311] In some embodiments, crystalline form B1 is substantially free of other polymorphic forms. In some embodiments, crystalline form B1 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.
[0312] In another embodiment, the invention relates to a mixture comprising a crystalline form B1 and a second solid form of a compound of formula (III). In some embodiments, the second solid form of the compound of formula (III) is the crystalline form A1.
[0313] In some embodiments, the invention relates to mixtures comprising a majority of the crystalline form B1 compared to other solid forms of the compound of formula (III). III. Pharmaceutical Compositions
[0314] Compounds of formula (I), 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) as disclosed herein, in their solid form and mixtures thereof, may be administered to mammals as chemical raw materials without any other components, or the compounds of the present invention may also be administered to mammals as part of a pharmaceutical composition containing the compound in combination with a suitable pharmaceutically acceptable carrier (see, for example, Gennaro, Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Plus, 20th edition (2003); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th edition, Lippencott Williams and Wilkins (2004); Kibbe et al., Handbook of Pharmaceutical Excipients, 3rd edition, Pharmaceutical Press (2000)). Such carriers can be selected from pharmaceutically acceptable excipients and adjuvants. The terms "pharmaceutically acceptable carrier" or "pharmaceutically acceptable medium" encompass any of the standard pharmaceutical carriers, solvents, surfactants, or mediums. Standard pharmaceutical carriers and their formulations are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 19th edition, 1995.
[0315] The solid forms of compounds of formula (I), formula (II) and formula (III) as disclosed herein, and mixtures thereof, may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, surface or percutaneous (e.g. via the use of patches) routes.
[0316] In some embodiments, the crystalline form A of compound (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal, and infusion techniques), rectal, intranasal, surface, or percutaneous (e.g., via the use of a patch) route.
[0317] In some embodiments, the crystalline form C of compound (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal, and infusion techniques), rectal, intranasal, surface, or percutaneous (e.g., via the use of a patch) route.
[0318] In some embodiments, the crystalline form D of the compound of formula (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, surface or percutaneous (e.g. via the use of a patch) route.
[0319] In some embodiments, the crystalline form E of the compound of formula (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal, and infusion techniques), rectal, intranasal, surface, or percutaneous (e.g., via the use of a patch) route.
[0320] In some embodiments, the crystalline form F of compound (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal, and infusion techniques), rectal, intranasal, surface, or percutaneous (e.g., via the use of a patch) route.
[0321] In some embodiments, the crystalline form 1 of the hydrochloride salt of compound (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, surface or percutaneous (e.g. via the use of a patch) route.
[0322] In some embodiments, the crystalline form 2 of the gentic acid cocrystal of compound (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, surface or percutaneous (e.g. via the use of a patch) route.
[0323] In some embodiments, the crystalline form 3 of the hydrochloride salt of compound (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, surface or percutaneous (e.g. via the use of a patch) route.
[0324] In some embodiments, the crystalline form 4 of the hydrobromide of compound (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, surface or percutaneous (e.g. via the use of a patch) route.
[0325] In some embodiments, the crystalline form 5 of the hydrobromide of compound (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, surface or percutaneous (e.g. via the use of a patch) route.
[0326] In some embodiments, the crystalline form 6 of the ethane disulfonate of compound (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal, and infusion techniques), rectal, intranasal, surface, or percutaneous (e.g., via the use of a patch) route.
[0327] In some embodiments, the crystalline form 7 of the methanesulfonate of compound (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, surface or percutaneous (e.g. via the use of a patch) route.
[0328] In some embodiments, the crystalline form 8 of the benzoic acid cocrystal of compound (II) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, surface or percutaneous (e.g. via the use of a patch) route.
[0329] In some embodiments, the salicylic acid cocrystal of Formula (II) in crystalline form 9 may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal, and infusion techniques), rectal, intranasal, surface, or percutaneous (e.g., via the use of a patch) route.
[0330] In some embodiments, the crystalline form A1 of compound (III) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal, and infusion techniques), rectal, intranasal, surface, or percutaneous (e.g., via the use of a patch) route.
[0331] In some embodiments, the crystalline form B1 of compound (III) may be administered to an individual via oral, non-enteric (such as subcutaneous, intravenous, intramuscular, intrasternal, and infusion techniques), rectal, intranasal, surface, or percutaneous (e.g., via the use of a patch) route.
[0332] In another embodiment, the present invention relates to a solid dosage form comprising one or more solid forms of compounds of formula (I), (II), and (III) as disclosed herein, and one or more pharmaceutically acceptable carriers or diluents. Solid dosage forms may include, but are not limited to, tablets, capsules, pills, granules, powders, packets, chewable tablets, and films.
[0333] In some embodiments, the present invention provides a solid dosage form comprising a compound of formula (I), a compound of formula (II), or a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein the solid dosage form is intended for use in a method of treating cancer.
[0334] In another embodiment, the present invention relates to a pharmaceutical composition comprising one or more solid forms of compounds of formula (I), formula (II) and formula (III) as disclosed herein, and one or more pharmaceutically acceptable carriers or diluents.
[0335] In some embodiments, the pharmaceutical composition comprises crystalline form A of compound (II). In some embodiments, the pharmaceutical composition comprises crystalline form C of compound (II). In some embodiments, the pharmaceutical composition comprises crystalline form D of compound (II). In some embodiments, the pharmaceutical composition comprises crystalline form E of compound (II). In some embodiments, the pharmaceutical composition comprises crystalline form F of compound (II).
[0336] In some embodiments, the pharmaceutical composition comprises the crystalline form 1 of the hydrochloride salt of compound (II). In some embodiments, the pharmaceutical composition comprises the crystalline form 2 of the gentianic acid cocrystal of compound (II). In some embodiments, the pharmaceutical composition comprises the crystalline form 3 of the hydrochloride salt of compound (II). In some embodiments, the pharmaceutical composition comprises the crystalline form 4 of the hydrobromide salt of compound (II). In some embodiments, the pharmaceutical composition comprises the crystalline form 5 of the hydrobromide salt of compound (II). In some embodiments, the pharmaceutical composition comprises the crystalline form 6 of the ethanedisulfonate salt of compound (II). In some embodiments, the pharmaceutical composition comprises the crystalline form 7 of the methanesulfonate salt of compound (II). In some embodiments, the pharmaceutical composition comprises the crystalline form 8 of the benzoic acid cocrystal of compound (II). In some embodiments, the pharmaceutical composition comprises the crystalline form 9 of the salicylic acid cocrystal of compound (II). In some embodiments, the pharmaceutical composition comprises the amorphous form of compound (II).
[0337] In some embodiments, the pharmaceutical composition comprises a mixture of two or more solid forms of a compound of formula (II).
[0338] In some embodiments, the pharmaceutical composition comprises the crystalline form A1 of the compound of formula (III). In some embodiments, the pharmaceutical composition comprises the crystalline form B1 of the compound of formula (III). In some embodiments, the pharmaceutical composition comprises the amorphous form of the compound of formula (III).
[0339] In some embodiments, the pharmaceutical composition comprises a mixture of two or more solid forms of a compound of formula (III).
[0340] In some embodiments, the pharmaceutical composition is an orally acceptable dosage form comprising one or more of the crystalline forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8 and 9 and the amorphous forms of the compound of formula (II).
[0341] In some embodiments, the pharmaceutical composition is an orally acceptable dosage form comprising one or more of the crystalline forms A1 and B1 and the amorphous form of the (III) compound.
[0342] In some embodiments, the orally acceptable dosage form may include, but is not limited to, capsules, tablets, aqueous suspensions, and solutions.
[0343] For oral administration, the pharmaceutical composition may include known carriers. For example, microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate, and glycine may be used, along with various disintegrants such as starch (preferably corn, potato, or cassava starch), methylcellulose, alginic acid, and certain complex silicates, and granulating binders such as polyvinylpyrrolidone, sucrose, gelatin, and gum arabic, and may be included in the tablet formulation. Additionally, lubricants such as magnesium stearate, sodium lauryl sulfate, and talc are commonly used for tablet formulation purposes. Similar types of solid compositions may also be used as fillers in gelatin capsules. In this regard, preferred materials include lactose (milk sugar) and high molecular weight polyethylene glycol. When an aqueous suspension and / or elixir is required for oral administration, the active ingredient may be combined with various sweeteners or flavorings, colorants or dyes, and, if necessary, with emulsifiers and / or suspending agents, along with diluents such as water, ethanol, propylene glycol, glycerin, and various similar combinations thereof.
[0344] In some embodiments, the pharmaceutical composition is an off-enteric compound comprising one or more of the crystalline forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8 and 9 and the amorphous forms of the compound of formula (II).
[0345] In some embodiments, the pharmaceutical composition is an off-enteric compound comprising one or more of the crystalline forms A1 and B1 and the amorphous form of the compound of formula (III).
[0346] For non-enteric administration, solutions containing compounds of formula (I), (II), or (III) in solid form can be prepared in sesame oil or peanut oil, in aqueous propylene glycol solution, or in sterile water or physiological saline. These aqueous solutions should be appropriately buffered (preferably with a pH greater than 8) and the liquid diluent should first be made isotonic with sufficient volume of physiological saline or glucose. These aqueous solutions are suitable for intravenous injection. Oily solutions are suitable for intra-articular, intramuscular, and subcutaneous injection. All such solutions can be readily prepared under sterile conditions using standard pharmaceutical techniques familiar to those skilled in this art.
[0347] In some embodiments, the pharmaceutical composition may be prepared as a liquid suspension or solution using liquids such as oil, water, alcohol, and combinations thereof.
[0348] In some embodiments, the pharmaceutical composition may be prepared as a sterile injectable preparation, which may be an aqueous or oily suspension. Such suspensions may be formulated according to techniques known in this art.
[0349] In some embodiments, the pharmaceutical composition may be administered in suppository form for rectal administration.
[0350] In some embodiments, the pharmaceutical composition may also be surface-applied, particularly when the therapeutic target includes areas or organs easily accessible by surface application, including eye, skin, or lower bowel diseases. Surface application to the lower bowel may be achieved in rectal suppository formulations (see above) or in suitable enema formulations. Surface-percutaneous patches may also be used. For surface application, these pharmaceutical compositions may be formulated as suitable ointments, lotions, or creams containing an active ingredient suspended or dissolved in one or more carriers.
[0351] In some embodiments, the pharmaceutical composition may also be administered ophthalmologically and formulated as a micronized suspension in isotonic, pH-adjusted sterile saline solution, or preferably as a solution in isotonic, pH-adjusted sterile saline solution, with or without a preservative such as benzyl chlorobenzyl ammonium. Alternatively, for ophthalmic use, the pharmaceutical composition may be formulated as an ointment, such as paraffin oil.
[0352] In some embodiments, the pharmaceutical composition may also be administered via nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the field of pharmaceutical formulation and can be prepared as a solution in physiological saline, using benzyl alcohol or other suitable preservatives, absorption enhancers to improve bioavailability, fluorocarbons and / or other known solubilizers or dispersants.
[0353] In some embodiments, the pharmaceutical composition intended for in vivo administration may be sterile. This can be easily achieved by filtration, for example, through a sterile filter membrane.
[0354] Pharmaceutical compositions within the scope of this invention include all compositions in which a compound of formula (I), formula (II), or formula (III) in solid form is combined with one or more pharmaceutically acceptable carriers or diluents. In one embodiment, the compound of formula (I), formula (II), or formula (III) in solid form is present in the composition in an amount sufficient to effectively achieve its intended therapeutic purpose.
[0355] The pharmaceutical compositions of the present invention can be administered to any patient who may experience the beneficial effects of the solid form of compound (I), compound (II), or compound (III). Among such patients, mammals, such as humans and companion animals, are most important, but the invention is not intended to be limited in this respect. In one embodiment, the patient is a human.
[0356] In another embodiment, the invention relates to a kit comprising a solid form of a compound of formula (I), formula (II), or formula (III), the solid form being packaged in a manner facilitating its use to practice the method of the invention. In one embodiment, the kit comprises a solid form of a compound of formula (I), formula (II), or formula (III) (or a combination thereof) packaged in a container (such as a sealed bottle or container), wherein a label describing the use of the compound or composition to practice the method of the invention is affixed to the container or included in the kit. In one embodiment, the compound or composition is packaged in a unit dosage form. The kit may further include a device suitable for administering the composition according to the intended route of administration. In some embodiments, the invention provides a kit comprising a solid form of a compound of formula (I), formula (II), or formula (III), or a pharmaceutically acceptable salt or solvate thereof, and a description relating to administering the compound or a pharmaceutically acceptable salt or solvate thereof to a patient with cancer.
[0357] In some embodiments, the present invention provides a pharmaceutical composition comprising a solid form of a compound of formula (I), a compound of formula (II) or a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or diluent, wherein the pharmaceutical composition is intended for use in a method of treating cancer. IV. Treatment Methods
[0358] The solid forms of compounds of formula (I), 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), and 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III), and mixtures thereof, can be used to inhibit the activity of the USP1 protein. For example, in some embodiments, a method of inhibiting the USP1 protein includes contacting the USP1 protein with the solid forms of compounds of formula (I), (II), (III), or combinations thereof. This contact can occur in vitro or in vivo.
[0359] In some embodiments, the solid form of compound (I), compound (II), or compound (III) can be used to treat "USP1 protein-mediated conditions". USP1 protein-mediated conditions are any pathological disorders in which the USP1 protein is known to play a role. In some embodiments, USP1 protein-mediated conditions are proliferative diseases, such as cancer.
[0360] This article provides various methods for treating diseases and conditions using compounds of formula (I), (II), or (III) in solid form. Examples of diseases and conditions that can be treated using these solid forms include, but are not limited to, cancer.
[0361] In some embodiments, a method of treating cancer with a compound of formula (I), formula (II), or formula (III) in solid form is provided. Such a method includes administering a therapeutically effective amount of a compound of formula (I), formula (II), or formula (III) in solid form to an individual with cancer.
[0362] In some embodiments, the cancer to be treated with the solid form disclosed herein is selected from hematologic malignancies, lymphomas, and cancers with DNA repair pathway defects. In some embodiments, the cancer to be treated comprises cancers containing cancer cells with mutations in the gene encoding p53. In some embodiments, the cancer to be treated comprises cancers containing cancer cells with loss-of-function mutations in the gene encoding p53.
[0363] In some embodiments, the cancer intended to be treated with the solid form disclosed herein is selected from non-small cell lung cancer (NSCLC), osteosarcoma, ovarian cancer, and breast cancer. In some embodiments, the cancer is ovarian cancer or breast cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is triple-negative breast cancer.
[0364] In some embodiments, the cancers to be treated with the solid form disclosed herein are selected from the group consisting of: bone cancer, including osteosarcoma and chondrosarcoma; brain cancer, including glioma, glioblastoma, astrocytoma, neuroblastoma and meningioma; soft tissue cancer, including rhabdomyosarcoma and sarcoma; kidney cancer; bladder cancer; skin cancer, including melanoma; and lung cancer, including non-small cell lung cancer.
[0365] In some embodiments, the present invention provides a method for treating cancer, comprising administering to a patient in need one or more solid forms disclosed herein. In some embodiments, the present invention provides a method for treating cancer, comprising administering to a patient in need one or more pharmaceutical compositions disclosed herein. In some embodiments, the present invention provides a method for treating cancer, comprising administering to a patient in need one or more solid dosage forms disclosed herein.
[0366] In some embodiments, the present invention provides a method for treating cancer, comprising administering to a patient in need a solid form or a medically acceptable salt thereof as disclosed herein, the solid form being selected from the group consisting of crystalline form A, crystalline form C, crystalline form D, crystalline form E, crystalline form F, crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 4, crystalline form 5, crystalline form 6, crystalline form 7, crystalline form 8, crystalline form 9, crystalline form A1, crystalline form B1, and mixtures thereof. In some embodiments, the present invention provides a method for treating cancer, comprising administering to a patient in need crystalline form A. In some embodiments, the present invention provides a method for treating cancer, comprising administering to a patient in need crystalline form F. In some embodiments, the present invention provides a method for treating cancer, comprising administering to a patient in need crystalline form 1. In some embodiments, the present invention provides a method for treating cancer, comprising administering to a patient in need crystalline form 2. In some embodiments, the present invention provides a method for treating cancer, comprising administering to a patient in need crystalline form 8. In some embodiments, the present invention provides a method for treating cancer, comprising administering crystalline form 9 to a patient in need. In some embodiments, the present invention provides a method for treating cancer, comprising administering crystalline form A1 to a patient in need. In some embodiments, the present invention provides a method for treating cancer, comprising administering crystalline form B1 to a patient in need.
[0367] In some embodiments, the present invention provides a method for treating breast cancer, comprising administering to a patient in need a solid form or a medically acceptable salt thereof as disclosed herein, the solid form being selected from the group consisting of crystalline form A, crystalline form C, crystalline form D, crystalline form E, crystalline form F, crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 4, crystalline form 5, crystalline form 6, crystalline form 7, crystalline form 8, crystalline form 9, crystalline form A1, crystalline form B1, and mixtures thereof. In some embodiments, the present invention provides a method for treating breast cancer, comprising administering to a patient in need crystalline form A. In some embodiments, the present invention provides a method for treating breast cancer, comprising administering to a patient in need crystalline form F. In some embodiments, the present invention provides a method for treating breast cancer, comprising administering to a patient in need crystalline form 1. In some embodiments, the present invention provides a method for treating breast cancer, comprising administering to a patient in need crystalline form 2. In some embodiments, the present invention provides a method for treating breast cancer, comprising administering to a patient in need crystalline form 8. In some embodiments, the present invention provides a method for treating breast cancer, comprising administering crystalline form 9 to a patient in need. In some embodiments, the present invention provides a method for treating breast cancer, comprising administering crystalline form A1 to a patient in need. In some embodiments, the present invention provides a method for treating breast cancer, comprising administering crystalline form B1 to a patient in need.
[0368] In some embodiments, the present invention provides a method for treating ovarian cancer, comprising administering to a patient in need a solid form or a pharmaceutically acceptable salt thereof as disclosed herein, the solid form being selected from the group consisting of crystalline form A, crystalline form C, crystalline form D, crystalline form E, crystalline form F, crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 4, crystalline form 5, crystalline form 6, crystalline form 7, crystalline form 8, crystalline form 9, crystalline form A1, crystalline form B1, and mixtures thereof. In some embodiments, the present invention provides a method for treating ovarian cancer, comprising administering to a patient in need crystalline form A. In some embodiments, the present invention provides a method for treating ovarian cancer, comprising administering to a patient in need crystalline form F. In some embodiments, the present invention provides a method for treating ovarian cancer, comprising administering to a patient in need crystalline form 1. In some embodiments, the present invention provides a method for treating ovarian cancer, comprising administering to a patient in need crystalline form 2. In some embodiments, the present invention provides a method for treating ovarian cancer, comprising administering to a patient in need crystalline form 8. In some embodiments, the present invention provides a method for treating ovarian cancer, comprising administering crystalline form 9 to a patient in need. In some embodiments, the present invention provides a method for treating ovarian cancer, comprising administering crystalline form A1 to a patient in need. In some embodiments, the present invention provides a method for treating ovarian cancer, comprising administering crystalline form B1 to a patient in need.
[0369] This document provides various methods for treating cancer with compounds of formula (I), (II), or (III). In some embodiments, a therapeutically effective amount of a compound of formula (I), (II), or (III) is administered to an individual with cancer comprising cancer cells having elevated levels of RAD18. In some embodiments, the elevated RAD18 level refers to an elevated level of RAD18 protein. In some embodiments, the elevated RAD18 level refers to an elevated level of RAD18 mRNA. In some embodiments, the elevated RAD18 level (e.g., RAD18 protein and / or RAD18 mRNA) has been detected prior to administration (e.g., in a cancer sample obtained from the individual). That is, in some embodiments, the individual's cancer has been tested for RAD18 protein or mRNA before treatment with a USP1 inhibitor is initiated.
[0370] In some embodiments, such methods for treating cancer include (a) identifying cancer in an individual as USP1 inhibitor-sensitive cancer, and then (b) administering to the individual a therapeutically effective amount of a compound of formula (I), formula (II), or formula (III) in solid form.
[0371] In some embodiments, such methods include (a) detecting the level of RAD18 (e.g., RAD18 protein and / or RAD18 mRNA) in cancer cells (e.g., in a cancer sample obtained from the individual), and then (b) administering a therapeutically effective amount of compound (I), compound (II), or compound (III) to an individual with cancer comprising cells having elevated levels of RAD18.
[0372] In some embodiments, such methods include administering a therapeutically effective amount of a compound of formula (I), formula (II), or formula (III) to an individual with triple-negative breast cancer.
[0373] In some embodiments, a compound of formula (I), formula (II), or formula (III) is used to treat cancer, wherein the cancer is a homologous recombination defective cancer. In some embodiments, a compound of formula (I), formula (II), or formula (III) is used to treat cancer, wherein the cancer comprises cancer cells with mutations in the gene encoding p53. In some embodiments, a compound of formula (I), formula (II), or formula (III) is used to treat cancer, wherein the cancer comprises cancer cells with loss-of-function mutations in the gene encoding p53. In some embodiments, a compound of formula (I), formula (II), or formula (III) is used to treat cancer that is not defective in the homologous recombination pathway.
[0374] In some embodiments, a compound of formula (I), formula (II), or formula (III) is used to treat cancer, wherein the cancer is a BRCA1-mutant cancer. In some embodiments, a compound of formula (I), formula (II), or formula (III) is used to treat cancer, wherein the cancer is a BRCA2-mutant cancer. In some embodiments, a compound of formula (I), formula (II), or formula (III) is used to treat cancer, wherein the cancer is both a BRCA1-mutant cancer and a BRCA2-mutant cancer. In some embodiments, the cancer is neither a BRCA1-mutant cancer nor a BRCA2-mutant cancer. In some embodiments, the cancer is a BRCA1-deficient cancer. In some embodiments, the cancer is a BRCA2-deficient cancer. In some embodiments, the cancer is both a BRCA1-deficient cancer and a BRCA2-mutant cancer.
[0375] In some embodiments, a compound of formula (I), formula (II), or formula (III) is used to treat cancer, wherein the cancer is a PARP inhibitor-resistant cancer. In some embodiments, a compound of formula (I), formula (II), or formula (III) is used to treat cancer, wherein the cancer is a PARP inhibitor-resistant BRCA1-deficient cancer.
[0376] In some embodiments, the cancer is a BRCA1 and / or BRCA2 mutant cancer, wherein the cancer comprises cells with elevated RAD18 levels, for example, wherein the elevated RAD18 levels are at least as high as the RAD18 protein and / or mRNA levels in ES2 cells, or wherein the elevated RAD18 levels are higher than the RAD18 protein and / or mRNA levels in HEP3B217 cells. In some embodiments, triple-negative breast cancer is a BRCA1 and / or BRCA2 mutant cancer.
[0377] In some cases, the cancer is a solid tumor. In some cases, the cancer is a blood / lymphoma. In some cases, the cancer is a cancer with a defective DNA repair pathway. In some cases, the cancer is a cancer with a defective homologous recombination pathway. In some cases, the cancer comprises cancer cells with mutations in the gene encoding p53. In some cases, the cancer comprises cancer cells with loss-of-function mutations in the gene encoding p53. In some cases, the cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), osteosarcoma, ovarian cancer, and breast cancer (including triple-negative breast cancer). In some cases, the cancer is ovarian cancer or breast cancer (including triple-negative breast cancer). In some cases, the cancer is ovarian cancer. In some cases, the cancer is breast cancer (including triple-negative breast cancer).
[0378] In some embodiments, compounds of formula (I), (II), or (III) are used in combination with one or more additional therapeutic agents to treat cancer. It has been reported that p53 status determines PARP inhibitor sensitivity induced by ionizing radiation in various tumor types effective with BRCA1 and HR mechanisms (Sizemore et al., Mol. Cancer Res. 16: 1092-1102 (2018)). As described below, p53-mutant and BRCA-mutant cancers have increased sensitivity to USP1 inhibitors. Therefore, in some embodiments, compounds of formula (I), (II), or (III) are used in combination with PARP inhibitors to treat cancer.
[0379] In some embodiments, the present invention provides the use of one or more solid forms disclosed herein for manufacturing medicaments for treating cancer. In some embodiments, the present invention provides the use of one or more pharmaceutical compositions disclosed herein for manufacturing medicaments for treating cancer. In some embodiments, the present invention provides the use of one or more solid dosage forms disclosed herein for manufacturing medicaments for treating cancer.
[0380] In some embodiments, the present invention provides the use of one or more solid forms, or pharmaceutically acceptable salts thereof, as disclosed herein for the manufacture of a medicament for treating cancer, wherein the one or more solid forms are selected from the group consisting of crystalline forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8, 9, A1, B1, and mixtures thereof. In some embodiments, the present invention provides the use of crystalline form A for the manufacture of a medicament for treating cancer. In some embodiments, the present invention provides the use of crystalline form F for the manufacture of a medicament for treating cancer. In some embodiments, the present invention provides the use of crystalline form 1 for the manufacture of a medicament for treating cancer. In some embodiments, the present invention provides the use of crystalline form 2 for the manufacture of a medicament for treating cancer. In some embodiments, the present invention provides the use of crystalline form 8 for the manufacture of a medicament for treating cancer. In some embodiments, the present invention provides the use of crystalline form 9 for the manufacture of a medicament for treating cancer. In some embodiments, the present invention provides the use of crystalline form A1 for the manufacture of a medicament for treating cancer. In some embodiments, the present invention provides the use of crystalline form B1 for manufacturing a medicament for treating cancer.
[0381] In some embodiments, the present invention provides the use of one or more solid forms, or pharmaceutically acceptable salts thereof, as disclosed herein for the manufacture of an agent for treating breast cancer, wherein the one or more solid forms are selected from the group consisting of crystalline forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8, 9, A1, B1, and mixtures thereof. In some embodiments, the present invention provides the use of crystalline form A for the manufacture of an agent for treating breast cancer. In some embodiments, the present invention provides the use of crystalline form F for the manufacture of an agent for treating breast cancer. In some embodiments, the present invention provides the use of crystalline form 1 for the manufacture of an agent for treating breast cancer. In some embodiments, the present invention provides the use of crystalline form 2 for the manufacture of an agent for treating breast cancer. In some embodiments, the present invention provides the use of crystalline form 8 for the manufacture of an agent for treating breast cancer. In some embodiments, the present invention provides the use of crystalline form 9 for the manufacture of an agent for treating breast cancer. In some embodiments, the present invention provides the use of crystalline form A1 for manufacturing a medicament for treating breast cancer. In some embodiments, the present invention provides the use of crystalline form B1 for manufacturing a medicament for treating breast cancer.
[0382] In some embodiments, the present invention provides the use of one or more solid forms, or pharmaceutically acceptable salts thereof, as disclosed herein for the manufacture of an agent for treating ovarian cancer, wherein the one or more solid forms are selected from the group consisting of crystalline forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8, 9, A1, B1, and mixtures thereof. In some embodiments, the present invention provides the use of crystalline form A for the manufacture of an agent for treating ovarian cancer. In some embodiments, the present invention provides the use of crystalline form F for the manufacture of an agent for treating ovarian cancer. In some embodiments, the present invention provides the use of crystalline form 1 for the manufacture of an agent for treating ovarian cancer. In some embodiments, the present invention provides the use of crystalline form 2 for the manufacture of an agent for treating ovarian cancer. In some embodiments, the present invention provides the use of crystalline form 8 for the manufacture of an agent for treating ovarian cancer. In some embodiments, the present invention provides the use of crystalline form 9 for the manufacture of an agent for treating ovarian cancer. In some embodiments, the present invention provides the use of crystalline form A1 for manufacturing a pharmaceutical agent for treating ovarian cancer. In some embodiments, the present invention provides the use of crystalline form B1 for manufacturing a pharmaceutical agent for treating ovarian cancer.
[0383] In some embodiments, the present invention provides a solid form of a compound of formula (I), a compound of formula (II), or a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein the solid form is intended for use in a method of treating cancer.
[0384] In some embodiments, the present invention provides a solid form or a pharmaceutically acceptable salt thereof as disclosed herein, one or more solid forms selected from the group consisting of crystalline forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8, 9, A1, B1, and mixtures thereof, for use in a method of treating cancer. In some embodiments, the present invention provides crystalline form A for use in a method of treating cancer. In some embodiments, the present invention provides crystalline form F for use in a method of treating cancer. In some embodiments, the present invention provides crystalline form 1 for use in a method of treating cancer. In some embodiments, the present invention provides crystalline form 2 for use in a method of treating cancer. In some embodiments, the present invention provides crystalline form 8 for use in a method of treating cancer. In some embodiments, the present invention provides crystalline form 9 for use in a method of treating cancer. In some embodiments, the present invention provides crystalline form A1 for use in a method of treating cancer. In some embodiments, the present invention provides crystalline form B1 for use in a method of treating cancer.
[0385] In some embodiments, the present invention provides a solid form or a pharmaceutically acceptable salt thereof as disclosed herein, one or more solid forms selected from the group consisting of crystalline forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8, 9, A1, B1, and mixtures thereof, for use in a method of treating breast cancer. In some embodiments, the present invention provides crystalline form A for use in a method of treating breast cancer. In some embodiments, the present invention provides crystalline form F for use in a method of treating breast cancer. In some embodiments, the present invention provides crystalline form 1 for use in a method of treating breast cancer. In some embodiments, the present invention provides crystalline form 2 for use in a method of treating breast cancer. In some embodiments, the present invention provides crystalline form 8 for use in a method of treating breast cancer. In some embodiments, the present invention provides crystalline form 9 for use in a method of treating breast cancer. In some embodiments, the present invention provides crystalline form A1 for use in a method of treating breast cancer. In some embodiments, the present invention provides crystalline form B1 for use in methods for treating breast cancer.
[0386] In some embodiments, the present invention provides a solid form or a pharmaceutically acceptable salt thereof as disclosed herein, one or more solid forms selected from the group consisting of crystalline forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8, 9, A1, B1, and mixtures thereof, for use in a method for treating ovarian cancer. In some embodiments, the present invention provides crystalline form A for use in a method for treating ovarian cancer. In some embodiments, the present invention provides crystalline form F for use in a method for treating ovarian cancer. In some embodiments, the present invention provides crystalline form 1 for use in a method for treating ovarian cancer. In some embodiments, the present invention provides crystalline form 2 for use in a method for treating ovarian cancer. In some embodiments, the present invention provides crystalline form 8 for use in a method for treating ovarian cancer. In some embodiments, the present invention provides crystalline form 9 for use in a method for treating ovarian cancer. In some embodiments, the present invention provides crystalline form A1 for use in a method for treating ovarian cancer. In some embodiments, the present invention provides crystalline form B1 for use in methods for treating ovarian cancer. V. Preparation method
[0387] In one embodiment, the present invention relates to a method for preparing a solid form of a compound of formula (I), a compound of formula (II), or a compound of formula (III).
[0388] In some embodiments, the method includes: a) Add appropriate amounts of compound (I), compound (II), or compound (III) to an appropriate amount of suitable solvent system to obtain a suspension; b) Stir the suspension; and c) Collect the solid product from step b).
[0389] In some embodiments, a suitable pharmaceutically acceptable acid is added during step a).
[0390] In some embodiments, a suitable solvent system is selected from the group consisting of acetonitrile, acetone, cyclohexane, dichloromethane, dimethyl acetamide, dimethyl sulfoxide, ethanol, ethyl acetate, isopropanol, isopropyl acetate, methanol, methyl ethyl ketone, 4-methyl-2-pentanone, methyl tributyl ether, 2-methyltetrahydrofuran, n-heptane, n-methylpyrrolidone, tetrahydrofuran, toluene, water, and mixtures thereof. In some embodiments, the suitable solvent system is selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.
[0391] In some embodiments, the method includes: a) Dissolve an appropriate amount of compound (I), compound (II), or compound (III) in an appropriate amount of a suitable solvent to prepare a solution; b) Add an appropriate amount of suitable antisolvent; c) Adding seed crystals in solid form of a compound of formula (I), formula (II), or formula (III); d) The suspension obtained by stirring; and e) Collect the solid product produced in step d).
[0392] In some embodiments, the method further includes adding a suitable pharmaceutically acceptable acid during step a).
[0393] In some embodiments, the method further includes adding a suitable antisolvent after step c) and before step d).
[0394] In some embodiments, a suitable solvent and antisolvent are selected from the group consisting of acetonitrile, acetone, cyclohexane, dichloromethane, dimethyl acetamide, dimethyl sulfoxide, ethanol, ethyl acetate, isopropanol, isopropyl acetate, methanol, methyl ethyl ketone, 4-methyl-2-pentanone, methyl tributyl ether, 2-methyltetrahydrofuran, n-heptane, n-methylpyrrolidone, tetrahydrofuran, toluene, water, and mixtures thereof. In some embodiments, a suitable solvent and antisolvent are selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof. In some embodiments, the suitable solvent is ethyl acetate. In some embodiments, the suitable antisolvent is n-heptane.
[0395] In some embodiments, the compound of formula (I), the compound of formula (II), or the compound of formula (III) is added to a suitable solvent system at a temperature of about room temperature to about 100°C, or about room temperature to about 75°C, or about room temperature to about 50°C, or about room temperature to about 40°C. In some embodiments, the compound of formula (I), the compound of formula (II), or the compound of formula (III) is added to a suitable solvent system at about room temperature.
[0396] In some embodiments, the present invention relates to a method for preparing crystalline form 2 of the gentianic acid cocrystal of compound (II), the method comprising: a) At room temperature, add appropriate amounts of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentic acid to a suitable solvent system to obtain a suspension; b) Stirring the suspension from step a); and c) Collect the solid product from step b).
[0397] In some embodiments, the suitable solvent system is selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.
[0398] In some embodiments, the present invention relates to a method for preparing crystalline form 2 of the gentianic acid cocrystal of compound (II), the method comprising: a) Dissolve an appropriate amount of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentic acid in a suitable solvent at room temperature to prepare a solution; b) Add an appropriate amount of suitable antisolvent; c) Seed crystal of gentianic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine in addition to formula (II); d) The suspension obtained by stirring; and e) Collect the solid product produced in step d).
[0399] In some embodiments, the method further includes adding a suitable antisolvent after step c) and before step d).
[0400] In some embodiments, the suitable solvent is ethyl acetate. In some embodiments, the suitable antisolvent is n-heptane.
[0401] In one embodiment, the present invention relates to crystalline form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) prepared by any of the methods disclosed herein.
[0402] In another embodiment, the present invention relates to the crystalline form C of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) prepared by any of the methods disclosed herein.
[0403] In another embodiment, the present invention relates to the crystalline form D of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) prepared by any of the methods disclosed herein.
[0404] In another embodiment, the present invention relates to the crystalline form E of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) prepared by any of the methods disclosed herein.
[0405] In another embodiment, the present invention relates to the crystalline form F of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) prepared by any of the methods disclosed herein.
[0406] In another embodiment, the present invention relates to the crystalline form 1 of the hydrochloride salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) prepared by any of the methods disclosed herein.
[0407] In another embodiment, the present invention relates to the crystalline form 2 of the gentianic acid cocrystal of formula (II) of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine prepared by any of the methods disclosed herein.
[0408] In another embodiment, the present invention relates to the crystalline form 8 of the benzoic acid cocrystal of formula (II) of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine prepared by any of the methods disclosed herein.
[0409] In another embodiment, the present invention relates to the crystalline form 9 of the salicylic acid cocrystal of formula (II) 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine prepared by any of the methods disclosed herein.
[0410] In another embodiment, the present invention relates to the crystalline form A1 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) prepared by any of the methods disclosed herein.
[0411] In another embodiment, the present invention relates to crystalline form B1 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) prepared by any of the methods disclosed herein. Example A. Abbreviations and initials B. Experimental Methods Instrument conditions
[0412] X-ray powder diffraction (XRPD) patterns were measured using Cu-kα radiation on an X'Pert 3 X-ray powder diffractometer. Each sample was dispersed in the center of a zero-background silicon holder. The tube voltage and ampere were set to 45 kV and 40 mA, respectively. Continuous 2-θ (2θ°) scans were used, with a step size of 46.7 sec from 3° to 40° 2θ. The XRPD analysis conditions are shown in the table below.
[0413] For characterization of crystalline form F, XRPD patterns were measured using Cu-kα radiation on a PAnanlytical & Xpert 3 X-ray powder diffractometer. Each sample was dispersed in the center of a zero-background silicon holder. The tube voltage and ampere were set to 45 kV and 40 mA, respectively. Continuous 2-θ (2θ°) scans were used, with a step size of 20.96 sec from 2° to 50° 2θ. The XRPD analysis conditions are shown in the table below.
[0414] Thermogravimetric analysis (TGA) data were collected using a TA Q5000 and a Discovery TGA 5500 TGA from TA Instruments. The TGA analysis conditions are shown in the table below.
[0415] Differential scanning calorimetry (DSC) data were collected using a TA Q2000 DSC from TA Instruments. The DSC analysis conditions are shown in the table below.
[0416] For characterization of crystalline form F, DSC data were collected using a Perkin Elmer DSC 4000. The DSC analysis conditions are shown in the table below.
[0417] Images were captured using a ZEISS Scope A1 microscope for polarized light microscopy (PLM). Example 1: Preparation and characterization of crystalline form A A. Preparative compound (II)
[0418] The procedure disclosed in U.S. Provisional Patent Applications No. 62 / 783,014, No. 62 / 799,423, and No. 62 / 868,616 is used to prepare 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine.
[0419] Sodium hydride (60% dispersion in mineral oil) (1.2 eq) was added fractionally to an ice-cooled solution of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (1 eq) in dimethylformamide (5 mL), and the reaction mixture was stirred at the same temperature for 10 min. 2-Iodopropane (1.20 eq) was added to the resulting reaction mixture, and stirring was continued at room temperature for 16 h. The reaction progress was monitored by thin-layer chromatography (TLC) and liquid chromatography-mass spectrometry (LCMS). After completion, the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (2 × 200 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude compound was purified by preparative high-performance liquid chromatography (HPLC) to provide 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). The purified compound was then recrystallized in heptane and ethyl acetate using methods known to those skilled in the art. B. Characterization
[0420] The 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) obtained as discussed above was subjected to XRPD, TGA, and DSC analyses using the conditions described above. The obtained XRPD spectra, DSC patterns, and TGA patterns are shown in Figures 1-2, and the XRPD peaks are shown in Table 1 above.
[0421] Based on the XRPD spectrum shown in Figure 1 and the XRPD peaks shown in Table 1, as well as the crystal structure and DSC and TGA morphologies, the 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine hydrate of formula (II) obtained as discussed above was identified and named as crystalline form A. C. Crystal structure determination
[0422] Approximately 2.9 mg of crystalline form A was added to a 3 mL glass vial containing a 0.5 mL DCM / n-heptane (1:4, v / v) solvent mixture. The mixture was then agitated using an ultrasonic cleaner to accelerate dissolution. The resulting suspension was filtered, and the clear solution was transferred to a clean 4-mL shell-and-tube vial (44.6 mm × 14.65 mm). The vial was sealed with a PE-Plug with a pinhole. The vial was then placed in a fume hood at room temperature for slow evaporation. After one day of slow evaporation, blocky crystals were observed.
[0423] Suitable single crystals with good diffraction quality were selected from bulk crystal samples and encapsulated with Paratone-N (an oil-based cryoprotectant). The crystals were randomly oriented and mounted on polyester film rings, then immersed in a nitrogen flow at 120 K. Preliminary checks and data collection were performed on a Rigaku XtaLAB Synergy R (CuKα radiation, λ = 1.54184 Å) diffractometer, and analysis was conducted using the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software suite. Cell parameters and orientation matrices used for data collection were extracted and refined (using the T-vector Dirax algorithm) using the mounting angle of 49,260 reflections within the range of 3.563º < θ < 75.668º in the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software. Data were collected, with a minimum diffraction angle (θ) of 3.591º and a maximum diffraction angle (θ) of 76.011º at 120 K. The final point group integrity is 100%. The mean I / σ of the data is 69.7, and the highest resolution is truncated at 0.79 Å.
[0424] Each frame was integrated with CrysAlisPro (V1.171.40.19a, Rigaku, 2018). A total of 57,364 reflections were collected, of which 5,292 were unique. Lorentz and polarization corrections were applied to the data. Empirical absorption correction was performed using CrysAlisPro (V1.171.40.19a, Rigaku, 2018) with spherical harmonics performed in SCALE3 ABSPACK. At this wavelength (λ = 1.542 Å), the absorption coefficient μ of this material is 0.883 mm⁻¹, and the minimum and maximum transmittances are 0.94414 and 1.0000, respectively. The mean uniformity factor is 5.19% based on intensity.
[0425] The structure was solved in space group P2 1 / c using the ShelXT structure solver with Intrinsic Phasing and refined using the ShelXL (Version 2018 / 3) refinement package with full matrix least squares over F 2 contained in OLEX2. All non-hydrogen atoms were anisotropically refined. A riding model was used for geometric calculations and refinement of hydrogen atoms.
[0426] Calculated XRPD patterns for copper (Cu) radiation were generated using the Mercury Project and atomic coordinates, space group, and cell parameters derived from single-crystal structures. Crystal structure representations were generated using Olex2 and Diamond. Atomic thermal displacement ellipsoids were generated using ORTEP-III.
[0427] A suitable single crystal was isolated from the bulk crystal and selected based on the collection of X-ray diffraction data for the single crystal. The crystal system of this single crystal is monoclinic and the space group is P2 1 / c. The crystallographic data and refinement parameters are shown in Table 12.
[0428] As shown in Figure 20, the asymmetric unit of this single-crystal structure contains a free alkali compound molecule of formula (II) and a non-integer number of water molecules, indicating that crystalline form A is a hydrate. Based on the thermal parameters, the number of water molecules in the asymmetric unit is smoothly refined to 0.42. Example 2: Preparation and characterization of crystalline form C A. Preparation
[0429] Purify an appropriate amount of crystalline form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) with nitrogen (N2) for 20 minutes at 30°C to form a new crystalline form. B. Characterization
[0430] The new crystalline form was subjected to XRPD analysis using the conditions described above. The resulting XRPD spectrum is shown in Figure 3, and the XRPD peaks are shown in Table 2 above. Based on the XRPD spectrum shown in Figure 3 and the XRPD peaks shown in Table 2, the new crystalline form was determined to be anhydrous and named crystalline form C. Example 3: Preparation and characterization of crystalline form D A. Preparation
[0431] Under nitrogen atmosphere, an appropriate amount of crystalline form C of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) was heated to 150°C to form a new crystalline form. B. Characterization
[0432] The new crystalline form was subjected to XRPD analysis using the conditions described above. The resulting XRPD spectrum is shown in Figure 4, and the XRPD peaks are shown in Table 3 above. Based on the XRPD spectrum shown in Figure 4 and the XRPD peaks shown in Table 3, the new crystalline form was determined to be anhydrous and named crystalline form D. Example 4: Preparation and characterization of crystalline form E A. Preparation
[0433] Approximately 20 mg of crystalline form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) was placed in a 3 mL vial. This 3 mL vial was then transferred to a 20 mL vial containing approximately 4 mL of DCM. The 20 mL vial was sealed and kept at room temperature for 10 days. After 10 days, the resulting solution was evaporated at room temperature to obtain the solid material. B. Characterization
[0434] The obtained solid material was subjected to XRPD, TGA, and DSC analyses under the conditions described above. The obtained XRPD spectra, DSC patterns, and TGA patterns are shown in Figures 5-6, and the XRPD peaks are shown in Table 4 above.
[0435] Based on the XRPD spectrum shown in Figure 5 and the XRPD peaks shown in Table 4, as well as the DSC and TGA morphologies, the obtained solid material was determined to be a crystalline DCM solvate and named as crystalline form E. Example 5: Preparation and characterization of crystal form 1 A. Preparation
[0436] Approximately 20 mg of crystalline form A was mixed with hydrochloric acid at a 1:1 ratio in an HPLC vial. Then, 0.5 mL of EtOAc / n-heptane (1:1, v / v) was added to form a suspension, which was stirred at approximately 1000 rpm for about 3 days at room temperature. The resulting solid material was separated by centrifugation and dried under vacuum at room temperature. B. Characterization
[0437] The obtained solid material was subjected to XRPD, TGA, and DSC analyses under the conditions described above. The obtained XRPD spectra, DSC patterns, and TGA patterns are shown in Figures 7-8, and the XRPD peaks are shown in Table 6 above.
[0438] Based on the XRPD spectrum shown in Figure 7 and the XRPD peaks shown in Table 6, as well as the DSC and TGA morphologies, the obtained solid material is identified as the crystalline hydrate of the HCl salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), and is named crystalline form 1. Example 6: Preparation and characterization of crystal form 2 A. Preparation
[0439] Method A: Approximately 40 mg of crystalline form A and 11.6 mg of gentianic acid were combined with 0.5 mL of EtOAc / n-heptane to obtain a suspension. The suspension was stirred at room temperature for 2 days, and the solid material was separated by vacuum filtration and dried under vacuum at room temperature. The resulting solid material can be used as a "seed" for the large-scale preparation of crystalline form 1.
[0440] Method B: Approximately 500 mg of crystalline form A and 11.6 mg of gentic acid were combined with 7 mL of EtOAc to obtain a solution. Then, 5.0 mL of n-heptane was added dropwise, along with 10.2 mg of gentic acid cocrystal "seed crystals" prepared according to Method A, and finally 8.0 mL of n-heptane was added to obtain a suspension. The suspension was stirred at room temperature for two days. The resulting solid material was separated by vacuum filtration and dried under vacuum at room temperature. B. Characterization
[0441] The obtained solid material was subjected to XRPD, TGA, and DSC analyses under the conditions described above. The obtained XRPD spectra, DSC patterns, and TGA patterns are shown in Figures 9-10, and the XRPD peaks are shown in Table 7 above.
[0442] Based on the XRPD spectrum shown in Figure 9 and the XRPD peaks shown in Table 7, as well as the crystal structure and DSC and TGA morphologies, the obtained solid material system (II) of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine gentioic acid cocrystal was identified as crystalline form 2. C. Crystal structure determination
[0443] Approximately 3.0 mg of crystalline form 2 was added to a 3 mL glass vial containing a 0.5 mL THF / n-heptane (2:5, v / v) solvent mixture. The mixture was then agitated using an ultrasonic cleaner to accelerate dissolution. The resulting suspension was filtered, and the clear solution was transferred to a clean 4-mL shell-and-tube vial (44.6 mm × 14.65 mm). The vial was sealed with a PE-Plug with a pinhole. The vial was then placed in a fume hood at room temperature for slow evaporation. After 6 days of slow evaporation, blocky crystals were observed.
[0444] Suitable single crystals with good diffraction quality were selected from bulk crystal samples and encapsulated with Paratone-N (an oil-based cryoprotectant). These crystals were randomly oriented and mounted on polyester film rings, then immersed in a nitrogen stream at 120 K. Preliminary inspection and data collection were performed on a Rigaku XtaLAB Synergy R (CuKα radiation, λ = 1.54184 Å) diffractometer, and analysis was conducted using the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software suite. Cell parameters and orientation matrices used for data collection were extracted and refined (using the T-vector Dirax algorithm) using the mounting angle of 50053 reflections within the range of 3.539º < θ < 75.936º in the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software. Data were collected, with a minimum diffraction angle (θ) of 3.765º and a maximum diffraction angle (θ) of 76.018º at 120 K. The final point group integrity is 100%. The mean I / σ of the data is 75.8, and the highest resolution is truncated at 0.79 Å.
[0445] Each frame was integrated with CrysAlisPro (V1.171.40.19a, Rigaku, 2018). A total of 58,850 reflections were collected, of which 6,566 were unique. Lorentz and polarization corrections were applied to the data. Empirical absorption correction was performed using CrysAlisPro (V1.171.40.19a, Rigaku, 2018) with spherical harmonics performed in SCALE3 ABSPACK. At this wavelength (λ = 1.542 Å), the absorption coefficient μ of this material is 0.927 mm⁻¹, and the minimum and maximum transmittances are 0.75213 and 1.0000, respectively. The mean uniformity factor based on intensity is 3.94%.
[0446] The structure was analyzed in space group P2 1 / c using the ShelXT structure solver with Intrinsic Phasing and refined using the ShelXL (Version 2018 / 3) refinement package with full matrix least squares over F2 as included in OLEX2. All non-hydrogen atoms were anisotropically refined. Hydrogen atoms (H2) connected to oxygen atoms (O2) were smoothly identified and refined based on Fourier plots. Geometric calculations and refinement of other hydrogen atoms were performed using a riding model.
[0447] Calculated XRPD patterns for copper (Cu) radiation were generated using the Mercury Project and atomic coordinates, space group, and cell parameters derived from single-crystal structures. Crystal structure representations were generated using Olex2 and Diamond. Thermal ellipsoids were generated using ORTEP-III.
[0448] The crystal was separated from the bulk crystal and a suitable single crystal was selected based on the X-ray diffraction data collected from the single crystal. The crystal system of the single crystal was determined to be monoclinic and the space group was determined to be P2 1 / c. The crystallographic data and refinement parameters are listed in Table 13.
[0449] As shown in Figure 21, the asymmetric unit of the single crystal structure contains a neutral compound molecule of formula (II) and a gentian acid molecule, and its indicator crystal form 2 is actually a co-crystal of the starting compound and gentian acid. Example 7: Preparation and characterization of crystal form 3 A. Preparation
[0450] Approximately 20 mg of crystalline form A was mixed with hydrochloric acid at a 1:2 mole ratio (form A / acid) in an HPLC vial. Then, 0.5 mL of MTBE was added to form a suspension, which was magnetically stirred at RT (approximately 1000 rpm) for approximately 3 days. The resulting solid material was dried under vacuum at room temperature. B. Characterization
[0451] The resulting solid material was subjected to XRPD analysis under the conditions described above. The resulting XRPD pattern is shown in Figure 15. The new crystalline form was named crystalline form 3. Example 8: Preparation and characterization of crystal form 4 A. Preparation
[0452] Approximately 20 mg of crystalline form A was mixed with hydrobromic acid at a 1:1 molar ratio (form A / acid) in an HPLC vial. Then, 0.5 mL of MTBE was added to form a suspension, which was magnetically stirred at RT (approximately 1000 rpm) for approximately 3 days. The resulting solid material was dried under vacuum at room temperature. B. Characterization
[0453] The resulting solid material was subjected to XRPD analysis using the conditions described above. The resulting XRPD pattern is shown in Figure 16. The new crystalline form was named crystalline form 4. Example 9: Preparation and characterization of crystal form 5 A. Preparation
[0454] Approximately 20 mg of crystalline form A was mixed with hydrobromic acid at a 1:1 molar ratio (form A / acid) in an HPLC vial. Then, 0.5 mL of EtOAc / n-heptane (1:1, v / v) was added to form a suspension, which was magnetically stirred at RT (approximately 1000 rpm) for approximately 3 days. The resulting solid material was dried under vacuum at room temperature. B. Characterization
[0455] The resulting solid material was subjected to XRPD analysis under the conditions described above. The resulting XRPD pattern is shown in Figure 17. The new crystalline form was named Crystalline Form 5. Example 10: Preparation and Characterization of Crystal Form 6 A. Preparation
[0456] Approximately 20 mg of crystalline form A was mixed with ethanedisulfonic acid at a 1:1 mole ratio (form A / acid) in an HPLC vial. Then, 0.5 mL of acetone / n-heptane (1:4, v / v) was added to form a suspension, which was magnetically stirred at RT (approximately 1000 rpm) for approximately 3 days. The resulting solid material was dried under vacuum at room temperature. B. Characterization
[0457] The resulting solid material was subjected to XRPD analysis under the conditions described above. The resulting XRPD pattern is shown in Figure 18. The new crystalline form was named Crystalline Form 6. Example 11: Preparation and characterization of crystalline form 7 A. Preparation
[0458] Approximately 20 mg of crystalline form A was mixed with methanesulfonic acid at a 1:1 molar ratio (form A / acid) in an HPLC vial. Then, 0.5 mL of acetone / n-heptane (1:4, v / v) was added to form a suspension, which was magnetically stirred at RT (approximately 1000 rpm) for approximately 3 days. The resulting solid material was dried under vacuum at room temperature. B. Characterization
[0459] The resulting solid material was subjected to XRPD analysis under the conditions described above. The resulting XRPD pattern is shown in Figure 19. The new crystalline form was named Crystalline Form 7. Example 12: Preparation and characterization of crystalline form A1 A. Preparation
[0460] The purified 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) was prepared according to the procedure disclosed in U.S. Provisional Patent Applications Nos. 62 / 783,014, 62 / 799,423, and 62 / 868,616. The purified compound was then recrystallized in hexane and isopropanol using methods known to those skilled in the art. B. Characterization
[0461] The 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) obtained as discussed above was subjected to XRPD, TGA, and DSC analyses using the conditions described above. The obtained XRPD spectra, DSC patterns, and TGA patterns are shown in Figures 11-12, and the XRPD peaks are shown in Table 10 above.
[0462] Based on the XRPD spectrum shown in Figure 11 and the XRPD peaks shown in Table 7, as well as the crystal structure and DSC and TGA morphologies, the 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine crystalline anhydrous form of formula (III) obtained as discussed above is identified and named as crystalline form A1. C. Crystal structure determination
[0463] Approximately 4.8 mg of crystalline A1 was added to a 3 mL glass vial containing a 0.5 mL EtOH / n-heptane (1:3, v / v) solvent mixture. After accelerating dissolution by agitation with an ultrasonic cleaner, the suspension was filtered and the resulting clear solution was transferred to a clean 4 mL shell-and-tube vial (44.6 mm × 14.65 mm). The vial was sealed with a PE-Plug with a pinhole. The vial was then placed in a fume hood at room temperature for slow evaporation. After 5 days of slow evaporation, fine rod-shaped crystals were observed.
[0464] Suitable single crystals with good diffraction quality were selected from a sample of thin rod-shaped crystals and encapsulated with Paratone-N (an oil-based cryoprotectant). The crystals were randomly oriented and mounted on polyester film rings, then immersed in a nitrogen stream at 120 K. Preliminary inspection and data collection were performed on a Rigaku XtaLAB Synergy R (Cu Kα radiation, λ = 1.54184 Å) diffractometer, and analysis was conducted using the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software suite. Cell parameters and orientation matrices used for data collection were extracted and refined (using the T-vector Dirax algorithm) using mounting angles of 24,455 reflections within the range of 3.516º < θ < 75.351º in the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software. Data were collected, with a minimum diffraction angle (θ) of 3.541º and a maximum diffraction angle (θ) of 75.982º at 120 K. The final point group integrity is 100%. The mean I / σ of the data is 71.4, and the highest resolution is truncated at 0.79 Å.
[0465] Each frame was integrated with CrysAlisPro (V1.171.40.19a, Rigaku, 2018). A total of 52,006 reflections were collected, of which 4,790 were unique. Lorentz and polarization corrections were applied to the data. Empirical absorption correction was performed using CrysAlisPro (V1.171.40.19a, Rigaku, 2018) with spherical harmonics performed in SCALE3 ABSPACK. At this wavelength (λ = 1.542 Å), the absorption coefficient μ of this material is 0.932 mm⁻¹, and the minimum and maximum transmittance are 0.72018 and 1.0000, respectively. The intensity of the equivalent reflections was averaged, and the consistency factor of the average was 3.24% based on the intensity.
[0466] The structure was analyzed in space group P2 1 / c using the ShelXT structure solver with Intrinsic Phasing, and refined using the ShelXL (Version 2018 / 3) refinement package with full matrix least squares over F2 as included in OLEX2. All non-hydrogen atoms were anisotropically refined. A riding model was used for geometric calculations and refinement of hydrogen atoms.
[0467] Calculated XRPD patterns for Cu radiation were generated using the Mercury Project and atomic coordinates, space group, and cell parameters derived from single-crystal structures. Crystal structure representations were generated using Olex2 and Diamond. Atomic thermal displacement ellipsoids were generated using ORTEP-III.
[0468] A suitable single crystal was isolated from a fine rod-shaped crystal, and selection was made based on the collection of X-ray diffraction data for the single crystal. The crystal system of the single crystal was determined to be monoclinic, and the space group was P2 1 / c. The crystallographic data and refinement parameters are listed in Table 14.
[0469] As shown in Figure 22, the asymmetric unit of this single crystal structure contains only one compound molecule of formula (III), which indicates that the crystalline form A1 is an anhydrous substance. Example 13: Preparation and characterization of crystalline form B1 A. Preparation
[0470] Approximately 20 mg of crystalline A1 was suspended in 0.5 mL of EtOAc / n-heptane (1:2, v / v) in an HPLC vial and magnetically stirred at RT (approximately 1000 rpm) for about 3 days. The resulting solid material was dried under vacuum at room temperature. B. Characterization
[0471] The obtained solid material was subjected to XRPD, TGA, and DSC analyses under the conditions described above. The obtained XRPD spectra, DSC patterns, and TGA patterns are shown in Figures 13-14, and the XRPD peaks are shown in Table 11 above.
[0472] Based on the XRPD spectrum shown in Figure 13 and the XRPD peaks shown in Table 8, as well as the DSC and TGA morphologies, the obtained solid material was determined to be a crystalline anhydrous substance and named as crystalline form B1. Example 14: Pharmacokinetic Study in Mice
[0473] Using the crystalline form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine as disclosed herein, and the crystalline form A of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine as disclosed herein, The crystalline forms 2 of gentiolic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and 8 of benzoic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine were used to conduct mouse pharmacokinetic (PK) studies.
[0474] These pharmacokinetic (PK) studies consisted of single-dose oral exposure studies conducted in female NOD / SCID mice (approximately 6 to 8 weeks old at the time of the study, and 20–30 g) using a compound dose of 300 mg / kg and an administration volume of 10 mL / kg. Mice were fasted overnight prior to administration. Animals had free access to food and water after administration.
[0475] Blood samples were continuously collected from the dorsal toe vein before drug administration and at 0.25, 0.5, 1, 2, 4, 8, 24, 48 (crystalline form 2 only) and 72 hours after PO administration (crystalline form 2 only). Approximately 0.03 mL of blood was collected at each time point and centrifuged at 4000 G for 5 minutes at 4°C to provide plasma. The plasma samples were then stored at -75 ± 15°C and subsequently analyzed by LC-MS / MS.
[0476] Next, LC-MS / MS was used to analyze the concentrations of each compound in the plasma samples. PK calculations were performed using WinNonlin (Phoenix™, version 6.1) or similar software. Where possible, the following PK parameters were calculated from plasma concentration versus time data: Cmax, Tmax, T1 / 2, AUCinf, and AUC. Finally, descriptive statistics, such as the mean with standard deviation, were used to describe the PK data.
[0477] The results for crystal form A are shown in Table 15 and Figure 23 below.
[0478] The results for crystal form 2 are shown in Table 16 and Figure 24 below. Example 15: Preparation and characterization of crystalline form F A. Preparation
[0479] The mixture of Formula II (1 g) in 50% acetone / water (10 vol) was heated to reflux and maintained at that temperature for at least 30 minutes. The resulting clear solution was then cooled to room temperature and stirred overnight. The resulting slurry was filtered and dried to provide form F (800 mg) as a white solid. B. Characterization
[0480] The resulting white solid material was subjected to XRPD and DSC analysis under the conditions described above. The obtained XRPD spectra and DSC patterns are shown in Figures 25 and 26, respectively, and the XRPD peaks are shown in Table 5.
[0481] Based on the XRPD spectrum shown in Figure 25, the XRPD peaks shown in Table 5, and the DSC morphology shown in Figure 26, the obtained solid material was determined to be a crystalline anhydrous substance and named as crystalline form F. Example 16: Additional Eutectic Screening
[0482] Additional eutectic screening was performed to identify other solid forms of formula (II). A. Instrument Configuration
[0483] Differential scanning calorimetry (DSC) was performed using a TA Instruments Q2000 instrument (enclosed aluminum sample pan with pinhole in the cover, heating rate 20 K / min). The melting point should be interpreted as the peak maximum value.
[0484] Optical microscopy is performed on the Leitz Orthoplan polarizing microscope part #130880, typically using a magnification of 10×10.
[0485] X-ray powder diffraction (XRPD) was performed using a Stoe Stadi P diffractometer equipped with a Mythen1K detector operating with Cu-Kα1 radiation. Measurements were performed in transmission mode using this instrument at a tube voltage of 40 kV and a tube power of 40 mA. A bent Ge monochromator allowed for testing with Cu-Kα1 radiation. The following parameters were set: 0.02° 2θ step size, 12 s step time, 1.5–50.5° 2θ scan range, and 1° 2θ detector step size (detector mode during step scan). For typical sample preparation, approximately 10 mg of sample was placed between two acetate foils and mounted in a Stoe transmission sample holder. The sample was rotated during measurement. All sample preparation and measurements were performed in ambient air.
[0486] TG-FTIR measurements were performed using a Netzsch Thermo-Microblanace TG209 coupled to a Bruker FTIR Spectrometer Vector 22 (sample disk with pinholes, N2 atmosphere, heating rate 10°C / min to 300 or 350°C). B. Starting materials
[0487] The starting material is the free alkali form of formula (II). Salt and eutectic screening
[0488] Cocrystal screening experiments using Formula II were conducted using adipic acid, benzoic acid, ethoxymethyl maltol, gallic acid (3,4,5-trihydroxybenzoic acid), ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, nicotinic acid, nicotinamide, L-proline, saccharin, salicylic acid, D-sorbitol, and succinic acid. The experimental parameters and results for the cocrystal screening experiments are listed in Table 17. Example 17: Characterization of Crystal Form 8 A. Characterization
[0489] The benzoic acid cocrystals from Experiment 5 in Table 17 were analyzed by XRPD, DSC, and TG-FTIR analysis under the conditions described above. The obtained XRPD spectra, DSC patterns, and TG-FTIR patterns are shown in Figures 29-31, and the XRPD peaks are shown in Table 8.
[0490] Based on the XRPD pattern shown in Figure 29 and the DSC and TGA morphologies, the obtained solid material was determined to be a benzoic acid eutectic and named as crystal form 8. B. Crystal structure determination
[0491] Approximately 82.4 mg of formula (II) benzoic acid cocrystal starting material was added to a 3-mL glass vial containing a 2.0 mL EtOAc / n-hexane (1:6, v / v) solvent mixture. The suspension was magnetically stirred at RT (1000 rpm) and filtered through a 0.45 μm PTFE membrane. 0.5 mL of the clarified filtrate was then transferred to a clean 4-mL shell-and-tube vial (44.6 mm × 14.65 mm). The vial was sealed with a PE-Plug with a pinhole and placed in a fume hood at room temperature for slow evaporation. After 14 days of slow evaporation, blocky crystals were obtained.
[0492] Suitable single crystals with good diffraction quality were selected from bulk crystal samples and coated with Paratone-N (an oil-based cryoprotectant). The crystals were randomly oriented and mounted on polyester film rings, then immersed in a nitrogen stream at 120 K. Preliminary examination and data collection were performed on a Rigaku XtaLAB Synergy R (Cu / K αX-ray radiation, λ = 1.54184 Å) diffractometer, and analysis was conducted using the CrysAlisPro (V1.171.40.67a, Rigaku, 2019) software suite.
[0493] Cell parameters and orientation matrices for data collection were extracted and refined using the T-vector Dirax algorithm with mounting angles of 37,110 reflections within the range of 3.716˚ < θ < 75.227˚ in CrysAlisPro (V1.171.40.67a, Rigaku, 2019). Data were collected with a minimum diffraction angle (θ) of 3.734° and a maximum diffraction angle (θ) of 76.055° at 120 K. Completeness was 100%. The average I / σ of the data was 64.1, and the highest resolution was truncated at 0.79 Å.
[0494] Each frame was integrated with CrysAlisPro (V1.171.40.67a, Rigaku, 2019). A total of 66,366 reflections were collected, of which 6,371 were unique. Lorentz and polarization corrections were applied to the data. Empirical absorption correction was performed using CrysAlisPro (V1.171.40.67a, Rigaku, 2019) with spherical harmonics performed in SCALE3 ABSPACK. At this wavelength (λ = 1.542 Å), the absorption coefficient μ of this material is 0.882 mm⁻¹, and the minimum and maximum transmittance are 0.7464 and 1.0000, respectively. The intensity of the equivalent reflections was averaged. Based on the intensity, the consistency factor of the average was 3.65%.
[0495] The structure in space group P21 / n was resolved using the ShelXT (Sheldrick, GM Acta Cryst. 2015, A71, 3-8) structure solver with Intrinsic Phasing and refined using the ShelXL (version 2018 / 3) refinement package (Sheldrick, GM Acta Cryst. 2015, C71, 3-8) with full matrix least squares over F2 contained in OLEX2 (Dolomanov, OV, Bourhis, LJ, Gildea, RJ, Howard, JAK and Puschmann, HJ Appl. Cryst. 2009, 42, 339-341). All non-hydrogen atoms were anisotropically refined. Hydrogen atoms (H2) connected to oxygen atoms (O2) were smoothly identified and refined based on Fourier plots. Geometric calculations and refinement of other hydrogen atoms were performed using a riding model.
[0496] Using the Mercury project (Macrae, CF, Edgington, PR, McCabe, P., Pidcock, E., Shields, GP, Taylor, R., Towler, M. and van de Streek, JJ Appl. Cryst. 2006, 39, 453–457) and atomic coordinates, space group and cell parameters from single-crystal structures, calculated XRPD patterns for Cu radiation were generated.
[0497] Crystal structure representations were generated using Olex2 and Diamond (Brandenburg, K. DIAMOND, 1999, Crystal Impact GbR, Bonn, Germany). Thermal ellipsoids were generated using ORTEP-III (LJ Farrugia. J. Appl. Cryst. 2012, 45, 849–854).
[0498] The crystal was separated from the bulk crystal and a suitable single crystal was selected based on the X-ray diffraction data collected from the single crystal. The crystal system of the single crystal was determined to be monoclinic and the space group was determined to be P2 1 / n. The crystallographic data and refinement parameters are shown in Table 18.
[0499] As shown in Figure 32, the asymmetric unit of this single crystal structure contains a neutral formula (II) molecule and a neutral benzoic acid molecule, which indicates the benzoic acid eutectic of the crystal system (II). Example 18: Characterization of Crystal Form 9 A. Characterization
[0500] The salicylic acid cocrystals from Experiment 29 in Table 17 were analyzed by XRPD and 1H NMR analysis under the conditions described above. The obtained XRPD and 1H NMR spectra are shown in Figures 33-34, respectively.
[0501] Based on the XRPD spectrum shown in Figure 33 and the 1H NMR morphology (Figure 34), the obtained solid material was determined to be a salicylic acid eutectic and named as crystal form 9. A. Crystal structure determination
[0502] Approximately 3.2 mg of formula (II) salicylic acid cocrystals were added to a 3-mL glass vial containing 0.5 mL of an acetone / n-heptane (1:8, v / v) solvent mixture. The solid sample was dissolved using ultrasound, followed by filtration of the suspension through a 0.45 µm PTFR membrane. The clarified filtrate was then transferred to a clean 4-mL shell-and-tube vial (44.6 mm × 14.65 mm). The vial was sealed with a PE-Plug with a pinhole. The vial was placed in a fume hood at room temperature for slow evaporation. After 2 days of slow evaporation, rod-shaped crystals were observed.
[0503] Suitable single crystals with good diffraction quality were selected from the rod-shaped crystal samples and coated with Paratone-N (an oil-based cryoprotectant). The crystals were randomly oriented and mounted on polyester film rings, then immersed in a nitrogen stream at 184 K. Preliminary inspection and data collection were performed on a Bruker D8 Venture (METALJET Ga X-ray source, PHOTON II) diffractometer, and analysis was conducted using the APEX3 software suite.
[0504] The cell parameters and orientation matrix used for data collection were extracted and refined using SAINT software (version: 8.37A) with mounting angles of 9918 reflections within the range of 3.252˚ < θ < 54.786˚. The collected data showed a minimum diffraction angle (θ) of 3.506˚ and a maximum diffraction angle (θ) of 55.323˚ at 184 K. The data completeness was 99.84%. The average I / σ of the data was 13.0, and the highest resolution was truncated at 0.82 Å.
[0505] Each frame was integrated with SAINT (version: 8.37A). A total of 38,333 reflections were collected, of which 6,058 were unique. Lorentz and polarization corrections were applied to the data. Absorption correction was performed using a multi-scan method with SADABS (version: 2016 / 2). At this wavelength (= 1.34139 Å), the absorption coefficient μ of this material is 0.579 mm⁻¹, and the minimum and maximum transmittances are 0.5107 and 0.7508, respectively. Based on intensity, the mean uniformity factor is 12.23%.
[0506] The structure was analyzed in space group P21 / c using the ShelXT 1 structure solver with Intrinsic Phasing and refined using the ShelXL 2 (version 2018 / 3) refinement package with full matrix least squares over F2 as included in OLEX2. All non-hydrogen atoms were anisotropically refined. Hydrogen atoms (H2) connected to oxygen atoms (O2) were smoothly identified and refined based on Fourier plots. Geometric calculations and refinement of other hydrogen atoms were performed using a riding model.
[0507] Calculated XRPD patterns for Cu radiation were generated using the Mercury Project and atomic coordinates, space group, and cell parameters derived from single-crystal structures. Crystal structure representations were generated using Olex2 and Diamond.
[0508] The crystal was separated from the bulk crystal and a suitable single crystal was selected based on the X-ray diffraction data collected from the single crystal. The crystal system of the single crystal was determined to be monoclinic and the space group was determined to be P2 1 / c. The crystallographic data and refinement parameters are listed in Table 19.
[0509] As shown in Figure 35, the asymmetric unit of the single crystal structure contains a neutral formula (II) molecule and a neutral salicylic acid molecule, which indicates the salicylic acid eutectic of the crystal system (II). Example 19: Pharmacokinetic Study in Mice
[0510] The crystalline form 8 of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, as disclosed in this paper, was used for mouse pharmacokinetic (PK) studies.
[0511] These pharmacokinetic (PK) studies consisted of single-dose oral exposure studies conducted in female NOD / SCID mice (approximately 6 to 8 weeks old at the time of the study, and 20–30 g) using a compound dose of 300 mg / kg and an administration volume of 10 mL / kg. Mice were fasted overnight prior to administration. Animals had free access to food and water after administration.
[0512] Blood samples were continuously collected from the dorsal toe vein before drug administration and at 0.25, 0.5, 1, 2, 4, 8, and 24 hours after PO administration. Approximately 0.03 mL of blood was collected at each time point and centrifuged at 4000 G for 5 minutes at 4°C to provide plasma. The plasma samples were then stored at -75 ± 15°C and subsequently analyzed by LC-MS / MS.
[0513] Next, LC-MS / MS was used to analyze the concentration of the compound in the plasma samples. PK calculations were performed using WinNonlin (Phoenix™, version 6.1) or similar software. The following PK parameters were calculated from plasma concentration versus time data whenever possible: Cmax, Tmax, T1 / 2, AUCinf, and AUC. Finally, descriptive statistics, such as the mean with standard deviation, were used to describe the PK data.
[0514] The results for crystal form 8 are shown in Table 20 and Figure 36 below. Example 20: Distribution of Crystal Form 2 in Mouse Brain and Plasma
[0515] Female NOD SCID mice aged 6–8 weeks and weighing 18–22 g were purchased from Beijing Anikeeper Biotech Co., Ltd. Animals were acclimatized to their environment for at least 7 days prior to the start of the study. Mice were administered the crystalline form at doses of 100 mg / kg or 300 mg / kg orally for 28 days. Twenty-four hours after the 27th dose, three mice were euthanized by CO2. Four hours after the 28th dose, three mice were euthanized by CO2. Whole brains were collected at each time point. Additionally, approximately 0.03 mL of blood was collected at each time point and centrifuged at 4000 G for 5 minutes at 4°C to provide plasma. Samples were then stored at -75 ± 15°C and subsequently analyzed by LC-MS / MS. The concentrations of the compound in brain homogenate (ng / g) and plasma (ng / ml) were then analyzed using LC-MS / MS. Use descriptive statistics to describe PK data, such as the mean with standard deviation.
[0516] As shown in Table 20 and Figure 37, measurable drug levels were observed in brain tissue. No significant drug accumulation in the brain was observed after repeated administration. Example 21. Distribution of Crystal Form 2 in Rat Brain and Plasma
[0517] Male and female Sprague Dawley rats were purchased from Beijing Anikeeper Biotech Co., Ltd. Animals were acclimatized to their environment prior to the start of the study. Two pairs of rats were administered a single dose of the crystalline form at 100 mg / kg via oral feeding. Rats were fasted overnight prior to administration. Animals were given food 2 hours after administration and had free access to water throughout the study. Approximately 0.2 mL of blood was sampled via the jugular vein at each time point and centrifuged at 4000 G for 5 minutes at 4°C to provide plasma. Samples were then stored in a freezer at -75 ± 15°C for subsequent LC-MS / MS analysis. Whole brains were collected after blood perfusion and flash-frozen on dry ice, then stored at -75 ± 15°C. Before LC-MS / MS analysis, the whole brain was weighed and homogenized with water at a 1:3 tissue weight (g):water volume (ml) ratio. Actual concentrations are calculated by multiplying the measured values by a dilution factor. Use descriptive statistics to describe PK data, such as the mean with standard deviation.
[0518] As shown in Table 21 and Figure 38, measurable drug levels were observed in brain tissue. A similar elimination pattern was also observed between plasma and brain tissue, indicating a rapid balance between systemic circulation and brain tissue.
[0519] The invention has been fully described, and those skilled in the art will understand that the same operation can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any of its embodiments.
[0520] Other embodiments of the invention will become apparent to those skilled in the art upon consideration of the description and practice of the invention disclosed herein. The description and examples are intended to be illustrative only, and the true scope and spirit of the invention are indicated by the following claims.
[0521] All patents and publications cited in this article are incorporated herein by full reference.
Claims
1. A solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II): (II), or a pharmaceutically acceptable salt thereof, wherein the solid form is a pharmaceutically acceptable cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and a pharmaceutically acceptable acid, wherein the pharmaceutically acceptable acid is gentic acid, and wherein the gentic acid cocrystal is in crystalline form 2, having XRPD spectra at 16.6 ± 0.2, 18.7 ± The peaks at 0.2 and 22.5 ± 0.2º 2θ, or wherein the solid form is a pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), wherein the pharmaceutically acceptable salt is a hydrochloride salt, wherein the hydrochloride salt is crystalline form 1, having peaks at 12.5 ± 0.2, 22.4 ± 0.2 and 23.9 ± 0.2º 2θ in the XRPD spectrum.
2. The solid form of claim 1, wherein the gentic acid eutectic has: (i) the XRPD pattern shown in Figure 9; or (ii) an endothermic peak at about 186.0 °C, as determined by DSC; or (iii) the DSC pattern shown in Figure 10; or (iv) a loss of about 3.17 wt% between room temperature and about 170 °C, as determined by TGA; or (v) the TGA pattern shown in Figure 10.
3. A mixture comprising the solid form of claim 1 and a second solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II).
4. The solid form of claim 1, wherein the hydrochloride has at least one of the following: a) an XRPD pattern as shown in Figure 7; b) an endothermic peak at about 142.1 °C, determined by DSC; c) the DSC pattern as shown in Figure 8; d) a loss of about 4.04 wt% between about 30 °C and about 100 °C, determined by TGA; or e) the TGA pattern as shown in Figure 8.
5. A mixture comprising the solid form of claim 1 or 4 and a second solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II).
6. The solid form of claim 1, wherein (i) the crystalline form 2 has a unit cell specified as monoclinic; (ii) the crystalline form 2 has a unit cell with a value of about 11.113 Å, a value of about 12.356 Å and a value of about 24.048 Å; or (iii) the crystalline form 2 has a unit cell with a volume of about 3223.93 Å3.
7. The solid form of any one of claims 1, 2, 4 and 6, wherein the solid form substantially does not contain any other polymorphic form.
8. A pharmaceutical composition comprising one or more of the solid forms or mixtures of any one of claims 1 to 4 and 6, and one or more pharmaceutically acceptable carriers or diluents.
9. A solid dosage form comprising one or more of the solid forms or mixtures of any one of claims 1 to 4 and 6.
10. Use of one or more of the solid form or mixture of any one of claims 1 to 4 and 6 in the manufacture of a pharmaceutical agent for the treatment of cancer.
Citation Information
Patent Citations
Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors
WO2020132269A1
